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ABSTRACT 
 
Epigenetic Modifications and Conserved, Non-Coding DNA Play a Role in Regulation 
of Type IV Collagen Gene Expression. 
(May 2008) 
Jessica Ashley Moody, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Keith E. Murphy 
 
 
Type IV collagens are components of basement membranes throughout the body 
and are involved in maintenance of the structural integrity of tissues as well as cellular 
differentiation, growth, and adhesion. Members of this collagen family are uniquely 
arranged in pairs in a head-to-head orientation and share a proximal promoter region. 
The COL4A5-COL4A6 gene pair is involved in numerous human diseases and cancer 
metastasis. For these reasons, defining the mechanisms that regulate collagen gene 
expression is of specific interest. To study type IV collagens, an in vitro model system 
was characterized. Comparative genomics was utilized to identify conserved, non-coding 
DNA in COL4A5 and COL4A6. These sequences were transfected into cell lines 
differing in type IV collagen expression and tested for the ability to regulate 
transcription of a reporter gene. Each cell line was also treated with the epigenetic 
modifying agents, 5-Aza and TSA. The effects on type IV collagen expression were 
determined. The COL4A5-COL4A6 promoter region was extensively characterized using 
ChIP analysis; antibodies against RNAPII, acetylated histone H3, and H3K9me2 were 
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used. Additionally, bisulfite sequencing was carried out on each cell line to determine 
the methylation status of CpG dinucleotides in the promoter.        
Cell lines differing in expression of COL4A5 and COL4A6 were identified: 1) 
SCC-25 keratinocytes and HEK-293 cells transcribed both COL4A5 and COL4A6, 2) 
HT-1080 cells selectively activated COL4A5, and 3) SK-N-SH neuroblastoma cells did 
not express either gene. In SK-N-SH cells, histone modifications were shown to 
facilitate formation of condensed chromatin to prevent transcription initiation; repression 
was independent of DNA methylation. Activation of COL4A5 and COL4A6 in SCC-25 
and HEK-293 cells involved acetylation of histones, although differences between the 
two cell types were seen. In addition, conserved, non-coding sequences were shown to 
affect transcription of a reporter gene; these sequences may be interacting with the 
transcription machinery to modulate collagen expression. Finally, repression of COL4A6 
in HT-1080 cells appeared to be mediated through DNA methylation of the promoter; 
selective activation of COL4A5 may involve conserved, non-coding DNA. In summary, 
epigenetic modifications as well as conserved sequences are intimately involved in 
regulation of type IV collagen gene expression.   
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NOMENCLATURE 
 
5-Aza 5-Aza-2′-deoxycytidine 
ChIP Chromatin immunoprecipitation 
CTD C-terminal domain 
GTF General transcription factor 
DNMT DNA methyltransferase  
HAT Histone acetyltransferase 
HDAC Histone deacetylase 
HMT Histone methyltransferase 
HP1 Heterochromatin protein 1 
MBD Methyl CpG binding domain 
ORF Open reading frame 
PIC Pre-initiation complex 
RNAPII RNA polymerase II 
TSA Trichostatin A 
TSS Transcription start site 
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CHAPTER I 
INTRODUCTION 
 
Type IV Collagen Background 
Type IV collagens are major constituents of basement membranes and function to 
maintain the structural integrity of tissues through associations with laminins, heparan 
sulfate proteoglycans, and nidogen. They are involved in filtration as well as cell 
differentiation, proliferation, and adhesion (1-3). The importance of type IV collagens is 
highlighted by their involvement in various human diseases including Alport syndrome, 
leiomyomatosis, nail-patella syndrome, Goodpasture’s disease, and benign familial 
hematuria (4-9). Table 1 summarizes important aspects of these conditions. 
In addition to those diseases described in Table 1, type IV collagens are known to 
play a significant role in cancer metastasis. They have been shown to be involved in 
prostate cancer, colorectal epithelial tumors, adenoid cystic carcinoma, breast cancer, and 
oral carcinogenesis (10-14). The anti-angiogenic property of type IV collagens functions 
to inhibit proliferation and migration of endothelial cells (15-18). Indeed, changes in 
composition and/or loss of type IV collagen proteins from the basement membrane are 
correlated with tumor invasiveness. These proteins can be used as a diagnostic marker 
and may provide researchers with a novel therapeutic target for the treatment of cancer.    
 
 
_____________ 
This dissertation follows the style of The Journal of Biological Chemistry. 
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Table 1 Summary of diseases involving the type IV collagens. Members of the type IV collagen family 
are involved in numerous human diseases. A brief description of several of these diseases as well as the 
associated clinical signs is presented here.  
 
Disease               Description                               Clinical Presentation 
 
Alport syndrome    - caused by mutations in COL4A3,        - renal failure often associated 
                                 COL4A4, and COL4A5                          with deafness and ocular 
                              - characterized by absence of or              lesions 
                                 aberrations in the α3.α4.α5(IV)  
                                 network 
 
Leiomyomatosis    - caused by deletions in parts of              - smooth muscle tumors and 
                                COL4A5 and COL4A6                             renal failure 
                              - characterized by absence of the 
                                α3.α4.α5(IV) and α5.α5.α6(IV) 
                                networks 
 
Benign familial      - caused by mutations in COL4A3          - hematuria and thin basement 
hematuria               and COL4A4                                            membranes 
                              - characterized by a reduction in the 
                               α3.α4.α5(IV) network 
 
Nail-patella           - caused by mutations in LMX1B, a        - skeletal abnormalities, nail hypoplasia, 
syndrome               transcription factor known to regulate     and nephropathy 
                               COL4A3, COL4A4, and nephrin genes  
 
Goodpasture’s      - caused by autoantibodies to the NC1   - characterized by pulmonary hemorrhage 
disease                   domain of α3(IV)                                     and crescentic  
                                                                                               glomerulonephritis                                     
                     
 
 
Type IV Collagen Genes 
Members of the type IV collagen family are designated α1(IV)- α6(IV) and are 
encoded by the genes COL4A1- COL4A6, respectively (19). These genes are unique in 
that they are arranged in pairs in a head-to-head orientation and share a bi-functional 
promoter. COL4A1-COL4A2, COL4A3-COL4A4, and COL4A5-COL4A6 are transcribed 
from opposite strands on human chromosomes 13, 2, and X, respectively (20,21). 
Organization of collagen genes is similar across mammalian species (22,23). Type IV 
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collagen genes are also present in invertebrates. The head-to-head arrangement is seen in 
the D. melanogaster genome; however, the genes are unpaired in C. elegans (24,25). 
 Based on the genomic arrangement and sequence data, the evolutionary history of 
type IV collagen genes can be deduced. The ancestral collagen gene underwent 
duplication and inversion. Following divergence, the gene pair was then duplicated as a 
single unit. One final round of duplication gave rise to another gene pair. Based on 
genomic sequences, two classes exist: the alpha 1-like class includes COL4A1, COL4A3, 
and COL4A5, while COL4A2, COL4A4, and COL4A6 are considered to be in the alpha 2-
like class (26).  
 
Type IV Collagen Proteins 
Type IV collagens are not functional as individual proteins. Instead, heterotrimers 
are formed through the association of different α-chains into a right-handed helix. 
Specific interactions among the protein domains help stabilize trimer formation. The 
three distinct domains that characterize type IV collagens are 1) the N-terminal 7S 
domain, 2) the collagenous domain, and 3) the C-terminal NC1 or non-collagenous 
domain (27,28). The 7S domain consists of approximately 140 amino acid residues and is 
involved in the higher order assembly of protomers through intra- and inter-molecular 
disulfide bonds. The collagenous domain consists of roughly 1300 amino acids and is 
characterized by Gly-Xaa-Yaa repeats, where Xaa is frequently proline and Yaa can be 
hydroxyproline or hydroxylysine. These repeats are periodically interrupted to confer 
flexibility and allow for the formation of a strong network (29). The NC1 domain, like 
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the 7S domain, functions to form intra- and inter-molecular disulfide bonds. 
Approximately 230 residues make up the NC1 domain, although the number does vary 
among isoforms (1).  
 
Type IV Collagen Trimers 
 Individual α-chains are synthesized as pro-collagen molecules consisting of non-
helical amino and carboxyl-terminal ends. These proteins undergo post-translational 
modification, including glycosylation and hydroxylation, to aid in stabilizing formation 
of the heterotrimer (30). Pro-collagen chains are brought together via interactions among 
the NC1 domains, and formation of the triple helix proceeds in a zipper-like fashion. 
While individual collagen proteins are left-handed, a heterotrimer is a right-handed helix. 
Upon secretion into the extracellular matrix, the terminal ends of the pro-collagen 
molecules are cleaved to allow formation of the network (29).  
 Although many different combinations are possible, only three heterotrimers can 
be formed: 1) α1.α1.α2(IV), 2) α3.α4.α5(IV), and 3) α5.α5.α6(IV). Experiments have 
shown that it is the discriminatory nature of the NC1 domain that is responsible for 
directing trimer formation (31). Significantly, if one α-chain is unavailable, the 
heterotrimer with which it is associated can not be formed. Instead, the other collagen 
molecules are degraded within the cell (32). 
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Network Formation and Distribution 
In the extracellular matrix, protomers (trimers) create a complex, cross-linked 
network through associations with other components of the basement membrane 
including laminins, heparan sulfate proteoglycans, and nidogen (1-3). Collagen protomers 
create networks through dimerization of the NC1 domain and tetramer formation at the 
7S domain (27,28). Nidogen functions to link individual networks of type IV collagen 
and laminin. Heparan sulfate proteoglycans play less of a structural role, but rather 
directly interact with cells through binding receptor molecules. Matrix metalloproteinases 
(MMPs) and their antagonist, tissue inhibitors of metalloproteinases (TIMPs), are 
responsible for collagen turnover (33,34).  
 There are three protomer networks, and each has a tissue-specific expression 
pattern. The α1.α1.α2(IV) network is formed through self-associations and is present 
ubiquitously in basement membranes throughout the body. The α3.α4.α5(IV) network 
also self-associates and is localized to the glomerular basement membrane as well as the 
basement membranes of the lungs, eyes, and ears (35-38).  The α1.α1.α2 α5.α5.α6(IV) 
network is found in the basement membranes of the skin, smooth muscles, and renal 
distal tubules (38-41). 
 
Regulation of Type IV Collagen Genes 
COL4A1-COL4A2 
 The genomic arrangement and/or tissue-specific expression patterns of the type 
IV collagen genes pose an intriguing question: how are these genes regulated? The 
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COL4A1-COL4A2 genes are separated by a ~127 bp promoter region that is insufficient 
to drive expression of either gene alone in vitro. Instead, downstream activating elements 
are necessary for efficient transcription (42). The TATA-less promoter is characterized 
by short, AT-rich motifs that are essential for transcription. Motifs for CCAATT binding 
protein, Sp1, and CTC binding factor (CTCBF) are present in the promoter as well as in 
introns 1 of both COL4A1 and COL4A2. Experiments have shown these proteins to bind 
to their respective motifs and work in concert to activate transcription (43). The CTC 
box, which is bound by CTCBF, is present near the TSS of several genes important in the 
extracellular matrix including COL4A5-COL4A6, COL1A1, laminin, and osteonectin. 
This represents a potential mechanism by which the expression of these genes may be 
coordinated (44,45). In addition to activating elements, a silencer in the third intron of 
COL4A2 has been identified (46). This 24 bp element is sufficient to inhibit transcription 
of both COL4A1 and COL4A2 through binding of SILBF. Inhibition is independent of 
relative position and orientation, thus SILBF is a true silencer.   
 Several lines of evidence suggest that the view of a bi-directional promoter for 
this gene pair should be reconsidered. Researchers have shown that although CCAAT 
binding factor, Sp1, and CTCBF are necessary for activation, they do not affect COL4A1 
and COL4A2 transcription equally. Specifically, mutations in binding sites for these 
proteins influence COL4A2 transcription more than COL4A1 (44). Other experiments 
have shown that the first introns in COL4A1 and COL4A2 compete for interactions with 
the promoter; constructs containing both introns and the promoter inhibit transcription of 
both genes in an in vitro setting (43). Taken together, these data suggest that the promoter 
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region should be viewed as two overlapping promoters that share cis-acting elements, but 
function in a uni-directional manner. 
 
COL4A3-COL4A4 
Much less is known about the regulation of COL4A3 and COL4A4. An enhancer 
sequence in intron 1 of COL4A4 binds LMX1B, a LIM homeodomain transcription factor 
encoded by the LMX1B gene, to activate expression of both COL4A3 and COL4A4. 
Mutations in LMX1B are causative for nail-patella syndrome, a disease in which patients 
present with skeletal abnormalities, nail hypoplasia, and nephropathy (7). 
 
COL4A5-COL4A6 
Investigating regulation of COL4A5 and COL4A6 expression is more complicated 
than the other type IV collagens because these genes are not always co-expressed. The 
human and murine promoter regions have been characterized, although much remains 
unknown concerning regulation. The human COL4A5-COL4A6 promoter region lacks the 
canonical TATA box and is characterized by CCAAT, CTC, and GC boxes (47,48). As 
has been shown for COL4A1 and COL4A2 these motifs are potential interaction sites with 
CCAAT binding protein, CTCBF, and Sp1, respectively. The relative locations of 
binding sites are presented in Figure 1. Experiments to determine the functional role of 
these proteins have yet to be carried out. The COL4A6 gene has two alternative 
promoters that are functionally separate from each other as well as the COL4A5 promoter 
(49).  
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COL4A6 A COL4A6 B 
COL4A5 
 
 
Figure 1 Relative locations of transcription factor binding sites in the collagen promoter. The relative 
locations of CCAAT, CTC, and GC boxes in the COL4A5-COL4A6 promoter region are shown. Open 
triangle, GC box; open square, CCAAT box; filled circle, CTC box.    
  
 
The murine COL4A5-COL4A6 promoter has previously been assessed for the 
ability to respond to different growth factors in a cell-based assay system (47). A reporter 
construct containing the promoter region was transfected into three cell lines differing in 
type IV collagen expression and treated with various growth factors. The construct was 
shown to respond to four different growth factors in a cell-type specific manner, although 
the exact mechanism by which these factors mediate changes in gene expression remains 
unknown. 
 The human COL4A5-COL4A6 promoter region has also been functionally 
characterized using a cell-based assay system (49). Constructs containing parts of the 
promoter were cloned upstream of the luciferase reporter gene and transfected into three 
cell lines differing in type IV collagen expression. As previously demonstrated, one 
COL4A5 and two COL4A6 promoters were shown to exist. All promoters were 
considered to be functionally separate; however, transcription was shown to be coupled 
through the presence of a bi-directional activator. This activator is thought to be non-
functional in the cell type where COL4A5 and COL4A6 were not expressed. In cells  
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COL4A6 
COL4A5 
Bi-directional  
activator 
COL4A6 
COL4A5 
Glomerular 
activator 
COL4A6 
COL4A5 
C 
B 
A BA
BA 
Figure 2 Proposed model for the regulation of type IV collagen genes. (A), Transcription of COL4A5 
and COL4A6 is coupled through binding of the bi-directional activator. (B), Absence or absence of binding 
of the bi-directional activator contributes to gene silencing. (C), Selective activation of COL4A5 is 
mediated through interactions between the glomerular activator and promoter. In addition, the bi-
directional is absent. (Adapted from Segal, 2001) 
 
 
where COL4A5 was selectively transcribed, the promoter construct was unable to drive 
expression of the reporter gene. Thus, it was proposed that absence of the bi-directional 
activator along with unidentified distal enhancers are necessary to account for the 
activation of COL4A5 without COL4A6 (49). This distal enhancer was named the 
glomerular activator because of the importance of this expression pattern in the 
glomerular basement membrane of the kidney. Figure 2 summarizes the proposed model 
of collagen regulation. 
In vivo experiments have also been conducted to characterize the human 
COL4A5-COL4A6 promoter (50). The functionality of reporter constructs containing the 
entire promoter region and sequences flanking the 5’-ends of COL4A5 and COL4A6 were 
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tested in transgenic mice. Specifically, a 10.6 kb fragment upstream of COL4A5 and 3.8 
and 13.8 kb fragments upstream of COL4A6 were assayed for the ability to turn on the 
lacZ reporter gene. These constructs were able to drive expression of the reporter gene 
only in the upper gastrointestinal tract. Because these genes are expressed in other tissues 
including the kidney, eye, and ear, additional unidentified regulatory sequences outside of 
the tested fragments are likely to exist (50).   
 
Eukaryotic Gene Regulation 
 There exists a seemingly endless number of ways to influence gene expression in 
eukaryotic cells. Chromatin structure, DNA methylation, histone modification, RNAPII, 
and transcription factors are all involved in modulating expression at the level of 
transcription. Post-transcription stages of regulation exist in the form of mRNA 
processing, degradation, transportation, and localization. Translation and post-
translational modifications represent additional layers of control. Although the end result 
of gene expression most definitely involves a number of different regulatory control 
mechanisms, only transcription and the associated players will be discussed further.    
 
Transcription 
 In general, transcription involves the binding of a sequence-specific activator to 
the promoter region. In addition to a DNA-binding domain, activators possess an 
activation domain necessary to assist in recruiting general transcription factors (GTFs) 
and proteins responsible for altering chromatin structure. DNA becomes more accessible, 
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and GTFs including TFIIA, B, D, E, F, and H assemble on the core promoter to form the 
pre-initiation complex (PIC). RNA polymerase II (RNAPII) is then positioned over the 
transcription start site (TSS). Core promoter elements and distal-acting enhancers work 
together with the PIC to coordinate transcription initiation. The C-terminal domain 
(CTD) of RNAPII is phosphorylated at serine 5, which recruits protein complexes that 
modify histones important for gene activation. Upon elongation, the CTD becomes 
phosphorylated at serine 2.  This modification recruits proteins necessary for elongation. 
These factors associate directly or indirectly with RNAPII to assist in transcription 
(51,52).  
 It is important to mention that the order of recruitment is not identical for every 
gene. In fact, the binding of certain sequence-specific activators is dependent upon 
chromatin modifying activities. Nevertheless, a coordinated effort among numerous 
players is necessary for proper activation of transcription (51).  
 
Chromatin and Histone Modifications 
Chromatin, in its simplest definition, is the complex association of nucleosomes 
and non-histone proteins with DNA. Chromatin is involved in DNA packaging to allow 
billions of bp to exist within the confines of the nucleus. Additionally, chromatin 
structure is associated with numerous biological processes including transcription, 
replication, DNA repair, and recombination. For these reasons, much research has been 
dedicated to understanding the regulation of nucleosome dynamics (51).  
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The basic unit of the nucleosome is an octamer of two copies of each of the four 
core histone proteins H2A, H2B, H3 and H4. Approximately 146 bp of DNA are 
wrapped around the histone octamer. Histone H1 exists outside of the nucleosome core to 
assist with DNA packaging. Histone proteins have globular and tail domains, which are 
subject to an array of post-translational modifications including acetylation, methylation, 
phosphorylation, and ubiquitination. A diverse set of enzymes are responsible for 
catalyzing these modifications, the functions of which are beginning to be revealed 
(53,54).       
The effects of covalent modifications on histone residues can be direct or indirect. 
Certain modifications alter charge, thereby influencing DNA-histone interactions to make 
DNA more or less accessible to transcription machinery. A modification can also act as a 
docking site for an effector protein to bind and elicit a specific response or it can actually 
prevent docking of non-histone proteins. Furthermore, modifications can recruit 
chromatin remodeling complexes, which use ATP hydrolysis to alter histone-DNA 
contacts (53). Table 2 summarizes post-translation modifications and their role in 
transcription. 
 
Acetylation 
 Acetylation of lysine residues is catalyzed by histone acetyltransferases (HATs) 
and is almost invariably associated with an open chromatin state and active transcription. 
In direct contrast, histone deacetylases (HDACs) function as global transcription 
repressors by removing acetyl groups. Addition of acetyl groups neutralizes the basic 
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charge on lysine, which presumably loosens DNA contacts with histones and makes 
histones more mobile. Subsequently, DNA becomes more accessible for recognition by 
various protein complexes and GTFs. Acetylated lysine residues also act as docking sites 
for proteins with bromodomains. Included among these are chromatin remodeling 
complexes and HATs, which can modify other lysine residues in the vicinity (53).  
 
Table 2 Summary of histone post-translational modifications. Histone residues are subject to hundreds 
of post-translational modifications, some of which are presented here along with their role in transcription. 
(Adapted from Berger, 2007) 
 
Chromatin Modifications Residues Effect on Transcription 
Acetylated lysine H3 (9, 14, 18, 56), H4 (5, 8, 13, 
16), H2A, H2B 
Activation 
Phosphorylated serine, threonine H3 (3, 10, 28), H2A, H2B Activation 
Methylated arginine H3 (17, 23), H4 (3) Activation 
Methylated lysine H3 (4, 36, 79) 
H3 (9, 27), H4 (20) 
Activation 
Repression 
Ubiquitylated lysine H2B (120) 
H2A (119) 
Activation 
Repression 
 
 
 Global acetylation patterns have been assessed in yeast as well as human cells. At 
the genome level, higher eukaryotic organisms generally have lower levels of acetylation 
and more heterochromatin, presumably due to the more specialized function of a given 
cell type (55,56). Despite these differences, the acetylation pattern for genes actively 
undergoing transcription is very similar and is characterized by high amounts of 
acetylation at the promoter and 5′ end of the coding region. In fact, more acetylation of 
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histones H3 and H4 correlates with higher transcription rates (57). Acetylation of lysine 
residues is also associated with known regulatory elements, DNase hypersensitive sites, 
and evolutionarily conserved sequences (56).  
 
Methylation 
 Histone methylation occurs at lysine and arginine residues and is catalyzed by 
histone methyltransferases (HMTs). Lysine can be mono-, di-, or tri-methylated, while 
arginine can exist in the mono- or di-methyl state. In contrast to acetylation, methylation 
does not alter charge, but rather acts as a docking site for effector proteins with 
chromodomains (53).  
Methylation is associated with both active and repressed transcription. In general, 
the response to methylation is dependent upon which residue is modified, the methylation 
state (mono-, di-, or tri-), and other modifications on nearby histones. Methylation of one 
residue can enhance or encourage the modification of another residue, known as histone 
crosstalk (53). In addition, localization of methylation is tightly regulated. For example, 
methylation of histone H3K36 occurs within the open reading frame (ORF) of actively 
transcribed genes and helps prevent cryptic initiation of transcription. If methylation of 
H3K36 is misdirected to the promoter region, transcription is repressed (51). Methylation 
of H3K9 has long been associated with gene silencing through binding of 
heterochromatin protein 1 (HP1). In light of new research, however, this relationship 
does not appear to be so simple. More specifically, di- and tri-methylated H3K9 in the 
ORF are associated with the gamma isoform of HP1 and active transcription, while 
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methylation targeted to the promoter regions correlates with gene silencing (58). The 
context driven nature of histone methylation makes assigning a function to a particular 
modification complicated.  
Methylated lysine residues have long been thought to represent a stable epigenetic 
mark; however, with the recent discovery of lysine demethylases, it is now known that 
this modification is reversible (59). Understanding the functional consequences and how 
this alters our current view of gene regulation are the subject of extensive research. 
Proteins that catalyze arginine demethylation have yet to be discovered, although arginine 
can be converted to citrulline resulting in the passive loss of methyl groups (60). 
 
Phosphorylation and Ubiquitination 
Histone residues are subject to phosphorylation and ubiquitination, although much 
less is known regarding the function of these modifications as compared to acetylation 
and methylation. Phosphorylation of serines or threonines results in a negative charge and 
is recognized by proteins containing a 14-3-3 domain. Ubiquitination is a rather large 
modification found on histones H2A and H2B and is associated with both active and 
repressed transcription (53). Undoubtedly, future research will focus on delineating the 
function of these modifications as they are likely to play an intimate role in regulating 
gene expression.  
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Methylation of DNA 
 DNA methylation represents yet another layer of regulatory control. In 
vertebrates, DNA methylation occurs almost exclusively in the context of CpG 
dinucleotides and is involved in genomic imprinting, X chromosome inactivation, 
carcinogenesis, and cellular differentiation. Methylation of DNA is also associated with 
repetitive DNA, transposons, and heterochromatin (61,62). 
 Early in mammalian development, the whole genome is demethylated. Around the 
time of implantation a wave of de novo methylation is carried out by the de novo 
methyltransferases (DNMTs) 3A and 3B. Methylation is propagated through subsequent 
cell divisions by maintenance DNMT1, which recognizes hemi-methylated DNA (62-64). 
Aberrations in methylation, such as hypermethylation of tumor suppressor genes, are 
associated with numerous cancers (65,66).     
 Approximately 60% of promoters are associated with CpG islands. CpG islands 
must 1) be 200 bp in length, 2) have a  G + C content of 50%, and 3) have a ratio of 
observed to expected CpG frequency of 0.6 (62). The dogma has been that regardless of 
expression these sites are unmethylated (67). Some genes, however, do exhibit tissue-
specific methylation patterns during development that inversely correlate with expression 
(68). Furthermore, experiments have shown that a subset of genes can be de-repressed by 
treating cells with agents that force global demethylation (69,70). It has also been 
demonstrated that gene activity can be repressed in vitro by methylation of promoter 
regions (71). These observations have lead scientists to propose that methylation of CpG 
dinucleotides plays a role in tissue-specific gene repression.    
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 There are several mechanisms by which methylated DNA can mediate gene 
silencing. Methylated DNA can recruit and bind regulatory proteins with methyl CpG 
binding domains (MBDs). One such protein, MeCP2, tethers a multi-protein repressor 
complex that includes HDACs to remove acetyl groups. Histone residues are 
subsequently methylated, thereby supporting a compact chromatin state (68). In another 
model, proteins with a MBD and SET domain recognize methylated DNA to directly 
methylate histones. It has also been shown that methylated histone tails can recruit 
DNMTs, which in turn methylate DNA (72,73). Finally, presence of methylated DNA 
can preclude binding of certain transcription factors and activators (74). Many factors 
have been shown to be sensitive to methyl CpG including AP-2, c-Myc, E2-F, and CREB 
(75).   
Several methods to silence genes by CpG methylation have been described; 
however, it is important to keep in mind that DNA methylation may also work in concert 
with other repressive mechanisms to keep genes in the inactive state.   
 
Comparative Genomics 
Historically, identification of cis-acting elements involved in gene regulation has 
been hindered by the limited availability of experimental approaches. Now, with access 
to numerous vertebrate whole genome sequences and bioinformatics analysis tools, 
researchers are in a position to systematically explore the biological relevance of non-
coding sequences through the use of comparative genomics. Comparative genomics 
aligns sequences from multiple species to identify regions of homology. This technique 
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has widely been used to identify coding boundaries, and is now being utilized to analyze 
non-coding DNA. Those regions that show evolutionary conservation in non-coding 
DNA are selectively constrained and, therefore, thought to be functional (76-79).  
To classify a sequence as conserved, non-coding, the extent of homology and the 
number of species that show conservation must be considered. Based on the recognized 
criteria, regions that show ≥ 70% homology between at least two species and are ≥ 100 
bp in length are considered to be conserved (78). It has been estimated that 3% of non-
coding sequence is conserved among distantly related mammals (80-82). Evidence from 
analyses using human genotype data suggests that these conserved, non-coding sequences 
are selectively constrained and do not represent mutational cold spots (83).  
A number of studies have successfully identified regions of conserved, non-
coding DNA that are functional and important in disease. Conserved, intronic sequences 
were found to regulate transcription of the breast cancer susceptibility gene, BRCA1, in 
an in vitro setting. BRCA1 is often down-regulated in breast cancer patients, so 
determining if and how these regions are involved in the development of this disease will 
be informative (84). In another study 45 conserved, non-coding sequences surrounding 
RET, a tyrosine kinase gene involved in development, were systematically examined 
using a cell-based assay approach. This study demonstrated the biological relevance of an 
evolutionarily conserved enhancer associated with Hirschsprung disease. Significantly, 
the majority of conserved, non-coding sequences surrounding the RET gene exhibited 
activity in vitro in a cell-type specific manner highlighting the fact that evolutionarily 
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conserved regions are of biological interest (85). More studies successfully using 
comparative genomics will likely be seen in the future.   
 
Summary 
There are ~35,000 genes in the human genome, only a fraction of which are 
expressed in a given cell type; therefore, unique mechanisms to control gene expression 
must exist (56,86). Indeed, eukaryotic cells are highly evolved to modulate expression at 
numerous levels including transcription, mRNA processing, and post-translation. 
Regulation of the type IV collagen genes, COL4A5 and COL4A6, must be tightly 
controlled to ensure tissue-specific patterns of expression. Previous research dedicated to 
understanding control of these genes has suggested that regulatory elements outside of 
the COL4A5-COL4A6 promoter exist. Comparative genomics has been successfully 
utilized to identify functionally significant, conserved, non-coding regions and will likely 
reveal cis-acting elements important in controlling collagen expression. In addition, 
evaluation of epigenetic modifications associated with the promoter region will shed light 
on COL4A5-COL4A6 regulation.  
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CHAPTER II 
MATERIALS AND METHODS 
 
Cell Culture 
Cell lines were obtained from American Type Culture Collection (ATCC, 
Manassas, VA) and maintained according to the manufacturer’s recommended protocols. 
HEK-293 cells (ATCC CRL-1573) were maintained in minimal essential Eagle’s 
medium with Earle’s balanced salt solution, non-essential amino acids, 2 mM L-
glutamine, 1 mM sodium pyruvate, and 1500 mg/L sodium bicarbonate, supplemented 
with 10% horse serum. HT-1080 cells (ATCC CCL-121) and SK-N-SH brain 
neuroblastoma cells (ATCC HTB-11) were maintained in minimal essential Eagle’s 
medium with Earle’s balanced salt solution, non-essential amino acids, 2 mM L-
glutamine, 1 mM sodium pyruvate, and 1500 mg/L sodium bicarbonate, supplemented 
with 10% fetal bovine serum. SCC-25 keratinocyte cells (ATCC CRL-1628) were 
maintained in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 
with 2.5 mM L-glutamine, 15 mM HEPES, 0.5 mM sodium pyruvate, and 1200 mg/L 
sodium bicarbonate, supplemented with 10% fetal bovine serum and 0.4 µg/mL 
hydrocortisone.  
 
RNA Isolation 
HEK-293, HT-1080, SCC-25, and SK-N-SH cells were collected and resuspended 
in 750 µl RNA STAT60 (Iso-Tex Diagnostics, Friendswood, TX). Total RNA was 
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isolated using the mirVana™ miRNA Isolation Kit (Ambion Inc., Austin, TX) following 
the manufacturer’s recommended protocol. Samples were quantified using the 
NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
 
Reverse Transcription 
Reverse transcription (RT) reactions were carried out on total RNA from HEK-
293, HT-1080, SCC-25, and SK-N-SH cells using the High Capacity cDNA Reverse 
Transcription Kit with RNase Inhibitor (Applied Biosystems Inc., Foster City, CA). Each 
20 µl RT reaction contained: 10 µl total RNA, 1X RT random primers, 20 U RNase 
Inhibitor, 1X RT buffer, 50 U MultiScribe™ reverse transcriptase, and 1 mM dNTPs. 
Reactions were run in an Eppendorf MasterCycler (Eppendorf North America Inc., New 
York, NY) for 10 minutes at 25°C, 120 minutes at 37°C, 5 seconds at 85°C, and then 
held at 4°C.   
 
Quantitative Real Time RT-PCR 
TaqMan® 
TaqMan® quantitative real time RT-PCR (qRT-PCR) was used to characterize all 
four cell lines for collagen expression and to determine relative expression levels 
following treatment with epigenetic modifying agents. Primers targeting the 3′ ends of 
COL4A5 and COL4A6 were used for these experiments. In addition, TaqMan® and 
primers targeting the 5′, middle, and 3′ sections of both collagens were used to assess 
how transcripts are processed. RNA was isolated and reverse transcribed as previously 
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mentioned. Each 20 µl qRT-PCR contained 10 ng RT product, 1X TaqMan® Universal 
PCR Master Mix (No AmpErase® UNG), and 1X TaqMan® assay, which contained the 
forward and reverse primers as well as the TaqMan® probe (Applied Biosystems Inc.). 
Primer and probe sets are listed in Table 3. Reactions were run in an Applied Biosystem 
7500 real time machine for 10 minutes at 95°C, followed by 40 cycles of 95°C for 15 
seconds and 60°C for one minute. 
 
Table 3 Primers for Taq Man® qRT-PCR. Pre-designed primers targeting exon-exon boundaries were 
used to quantify relative expression levels of COL4A5 and COL4A6. GAPDH was used as the 
normalization control. 
 
Gene ABI Assay No. Exon Boundary 
Hs00166712_m1 1-2 
Hs01012435_m1 28-29 
 
COL4A5 
Hs01012455_m1 50-51 
Hs00904472_m1 1-2 
Hs00904446_g1 26-27 
 
COL4A6 
Hs00904466_m1 44-45 
 
 
Syber Green  
 Syber Green was used to determine relative expression levels of the COL4A6 
transcript variants A and B in SCC-25 and HEK-293 cells. RNA was isolated and cDNA 
was made following above mentioned protocols. Each 25 µl Syber Green qRT-PCR 
contained 10 ng RT product, 1X SYBR® GREEN PCR Master Mix (Applied Biosystems 
Inc.), and 500 nM of each forward and reverse primer. Primer sequences are shown in 
Table 4. Reactions were run using the conditions described for TaqMan® qRT-PCR. In 
addition, dissociation curves were used to verify primer specificity. 
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Table 4 Primers for Syber Green qRT-PCR. Primers targeting COL4A6 transcript variants A and B were 
designed using ABI PRISM Primer Express (Applied Biosystems Inc.) and analyzed using BLAST (URL: 
http://www.ncbi.nlm.nih.gov/BLAST/). TBP was used as the normalization control. 
 
Gene Forward Primer Reverse Primer 
COL4A6 A CTGCTGGTCTTCTTTACCTTCCA CAATATTTTCACATCTTCTGCTTGTATG
COL4A6 B CTGAGTAAGGAAACAGCCTCCAA GCGGCCCGTGCTCAT 
 
 
qRT-PCR Analysis 
Relative quantification of gene expression was determined by utilizing the 
comparative critical threshold (CT) method. CT values corresponding to mRNA transcript 
levels were subtracted from the respective CT values of the normalization control, 
resulting in ∆CT values. GAPDH and TBP were used as normalization controls for 
TaqMan® and Syber Green, respectively. The largest ∆CT value was arbitrarily used as a 
constant and subtracted from all other ∆CT values to determine ∆∆CT values.  Fold 
changes were then determined by calculating 2 -∆∆CT. A two-tailed t-test was used to 
determine the level of statistical significance.  
 
Identification of Conserved, Non-Coding DNA 
Approximately 307 kb of genomic sequence encompassing human COL4A5 and 
COL4A6 (chrX: 107,519,809-107,827,431; University of California, Santa Cruz, March 
2006, hg18) was compared to the orthologous sequences of 6 non-human vertebrates 
(chimpanzee, rhesus, mouse, rat, dog, and cow). The human sequence was also compared 
to the genomes of seven non-human vertebrates (armadillo, elephant, tenrec, rabbit, 
chicken, opossum, and zebrafish), where COL4A5 and COL4A6 have not been annotated. 
Comparisons were conducted using the University of California, Santa Cruz Genome 
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Bioinformatics program (URL: http://genome.ucsc.edu/). Conservation scores were based 
on the phylogenetic hidden Markov model. Sequences that were ≥ 100 bp in length and 
exhibited ≥ 70% sequence identity between the human and at least one other vertebrate 
were classified as conserved. Sequences that did not overlap exons were considered to be 
non-coding. In addition, conserved, non-coding sequences were compared to their 
respective genomes using BLAST to eliminate any repetitive elements. Conserved, non-
coding regions were designated according to their positions relative to the COL4A5 TSS. 
 
Cloning of Conserved, Non-Coding DNA 
Primers were designed and analyzed using NetPrimer (URL: 
http://www.premierbiosoft.com/netprimer /index.html) to amplify conserved, non-coding 
sequences individually (Table 5). In addition, a primer set was designed to amplify a non-
conserved, non-coding sequence. XhoI restriction sites were added to the 5′ ends of both 
primers. Each PCR contained: 50 ng human genomic DNA, 1X Buffer B, 1.5 mM 
MgCl2, 0.5 mM dNTP mix, 1 µM of each primer, and 1 U Taq DNA Polymerase (Fisher 
Scientific, Pittsburg, PA). Reactions were run in an Eppendorf MasterCycler for 5 
minutes at 94°C, 30 seconds at 55°C, 30 seconds at 72°C followed by 34 cycles of 30 
seconds at 94°C, 30 seconds at 63°C, and 30 seconds at 72°C. PCR products were gel 
purified using the QIAEX II Gel Extraction kit (Qiagen, Valencia, CA) and digested with 
XhoI (Promega Corp., Madison, WI) following the manufacturers’ protocols. Digests 
were then purified using the QIAquick PCR Purification kit (Qiagen). The pGL3- 
 Table 5 Primers to amplify conserved, non-coding sequences. Forward and reverse primer sequences to amplify each conserved region are shown. 
Each construct is designated by its location with respect to the COL4A5 transcription start site (+1). The coordinates and amplicon sizes of each 
conserved, non-coding sequence are also shown.   
 
Construct Coordinates of    Forward primer (5′-3')  Reverse Primer (5'-3')       Amplicon 
  conserved non-coding                   size (bp) 
  sequences 
 
-43K  107526375-107526477  TGTGGAAGATACGATGTGTAAGAC  AAACTGTTCACTTTGGACATTCTA 1,119 
  107526212-107526321 
 
-41K  107528021-107528140  CCTTCTGCTTATTCTGCCC   GTCCTTGCTGTAGTGTTGTCC 1,193 
 
-40K  107529361-107529585  AATAGAATGGCTTTCAGGC   GAAGGAGGCACATAAGTAGG 870 
 
-28K  107540919-107541022  CCCTATCACAGACAAGACAA  ACATTTTCACCAAGAACTCA 561 
 
-25K  107543904-107544042  CTCTCAACAAGGCTCTCCAG  CAAAGACTGAAGGCAATGTAGG 643 
 
-110  107569568-107569698  TAAAGAAGACCAGCAGCCC   AGAGGGACAGTGAGGCTTG  572 
  107569709-107569809 
   
16K  107644613-107644713  CCAAGTGAAGATGTAGAACG  TAGCAACAAGTAACTAAAAATAAA 722 
 
21K  107590796-107590931  GTAGAGATGCGATTTCACCA  CCATCTGAGGGGAAAAAA  644 
 
25K  107594560-107594741  TTTATTTCTTAGGAGGCTTCTTA  AAACGGAACTTTTTGGGG  537 
 
76K  107646097-107646337  TTCTTCTTTGCTGCCTGTG   ACCGTAGGCTAACACTTGAAC 875 
 
120K  107689280-107689403  TAGGTGTCACATCAACTAAAAAG  TTATGTTTCTCACTCAGGTCC 828 
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Table 5 Continued 
 
Construct Coordinates of    Forward primer (5'-3')  Reverse Primer (5'-3')       Amplicon 
  conserved non-coding                   size (bp) 
  sequences 
 
136K  107706515-107706630  GAAGAGCAAAAGCAGGGC   GCCACAATGGTTGAGGAAA  666 
 
179K  107748548-107748753  ATCTATGCTATGGGAGGAAGT  GCCCTAAACTGACAAAATCC 965 
 
216K  107785542-107785654  CCAACCAGTATCACAGAGCAG  GCCTGGGCATACCTTTCT  318 
 
230K  107800008-107800158  GAAGCCATTAGTCACAAAGAT  GTAAGGCTGTTTTCGGTACT 748 
 
235K 107804508-107804758  TTGAAGGCTGTTGGTGAA   CAGGGCAATCTGAGAAAAC  756 
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Promoter vector (Promega Corp.) was digested with XhoI and treated with Shrimp 
Alkaline Phosphatase (Roche, Basel, Switzerland) according to the recommended 
protocols. Linearized vector was gel purified using the QIAEX II Gel Extraction kit 
(Qiagen). PCR products were cloned into the pGL3-Promoter vector using T4 DNA 
Ligase (Promega Corp.) and transformed into TOP10 competent cells (Invitrogen Corp., 
Carlsbad, CA). The GenElute™ Endotoxin-free Plasmid Midiprep kit (Sigma-Aldrich 
Co., St. Louis, MO) was used for large-scale isolation of plasmid DNA. Isolations were 
carried out following the manufacturers’ protocol, and samples were quantified using the 
NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies). Clones were 
sequence verified following the protocol outlined below.   
 
Sequencing 
Sequencing reactions were performed with the BigDye Terminator kit and 
resolved on an ABI3100 automated sequencer (Applied Biosystems Inc.). Sequence reads 
were aligned with the appropriate reference sequences via CLUSTAL W 
(http://www.ebi.ac.uk/clustalw/). 
 
Transient Transfections  
HEK-293, HT-1080, SCC-25, and SK-N-SH cells were co-transfected with 
pGL3-Promoter and phRG-TK vectors (Promega Corp.). The pGL3-Promoter vector 
contains the complete firefly (Photinus pyralis) luciferase open reading frame under 
control of the SV40 promoter. The phRG-TK vector has the pGL3 backbone and contains 
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the complete Renilla (Renilla reniformis or sea pansy) luciferase open reading frame 
downstream of the TK promoter. The phRG-TK vector was used as the normalization 
control to account for differences in transfection efficiencies. Cells were cultured as 
previously mentioned and transfected using Lipofectamine 2000 (Invitrogen Corp.) 
following the recommended protocol. Approximately 2.5 X 105 HEK-293, 1.2 X 105 HT-
1080, 6.0 X 105 SCC-25, and 8.0 X 104 SK-N-SH cells were plated the day before 
transfections.  HEK-293, HT-1080, and SK-N-SH cells were transfected with 800 ng 
total DNA using 2.0 µl Lipofectamine 2000 (Invitrogen Corp.). SCC-25 cells were 
transfected with 6.0 µg total DNA using 10.0 µl Lipofectamine 2000 (Invitrogen Corp). 
The firefly to Renilla ratio was 10:1 for SK-N-SH cells, and a 20:1 ratio was used for the 
remaining cell types. The Dual-Glo Luciferase Assay System (Promega Corp.) was used 
in accordance with the manufacturer’s protocol, and the Packard LumiCount™ (Packard 
Instrument Co., Meriden, CT) was used to measure firefly and Renilla luminescence 24 
hours post-transfection. Each pGL3-construct was transfected in duplicate on at least 
three separate occasions, and relative luciferase units (RLUs) were determined.  
 
Treatment with 5-Aza-2′-deoxycytidine and Trichostatin A 
HEK-293, HT-1080, SCC-25, and SK-N-SH cells were treated with 1) 5 µM 5-
aza-2′-deoxycytidine (5-Aza) for 72 hours, 2) 300 nM trichostatin A (TSA) for 24 hours, 
and 3) 5 µM 5-Aza for 48 hours followed by addition of 300 nM TSA for 24 hours. 
Media was renewed every 24 hours for the 5-Aza and 5-Aza plus TSA treatment groups. 
After treatment, cells were harvested and RNA was isolated and reverse transcribed. 
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Quantitative RT-PCR was performed using TaqMan® and primers specific for the 3′ 
ends of the COL4A5 and COL4A6 transcripts. Relative expression levels were determined 
using the ∆∆Ct method and represented as relative fold changes as compared to the 
control. Experiments were carried out as previously described.     
 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation (ChIP) assays were carried out on HEK-293, HT-
1080, SCC-25, and SK-N-SH cell lines. Cells were grown in 10 cm plates and fixed with 
1% formalin for 10 minutes at 37°C. Crosslinking was stopped by addition of 125 mM 
glycine. Cells were then washed with PBS and complete protease inhibitors (Roche), 
pelleted at 2,000 rpm for 4 minutes at 4°C, and resuspended in 200 µl SDS lysis buffer 
plus complete protease inhibitors for every 1 X 106 cells. Samples were incubated on ice 
for 10 minutes and sonicated. Samples were centrifuged for 10 minutes at 13,000 rpm at 
4°C, and supernatants were collected. Chromatin was then diluted 5-fold with ChIP 
dilution buffer, and complete protease inhibitors were added. Samples were pre-cleared 
twice with salmon sperm DNA/protein A agarose-50% slurry and incubated overnight at 
4°C with antibody. Approximately 10 µg of each of the following antibodies were used: 
anti-RNA polymerase II (Upstate Cell Signaling, Billerica, MA), anti-acetyl histone H3 
(Upstate Cell Signaling), and anti-dimethyl lysine 9 (Abcam Inc., Cambridge, MA). Anti-
HP1 was used in SK-N-SH cells (Upstate Cell Signaling). The following day, samples 
were incubated with salmon sperm DNA/protein A agarose-50% slurry for 1 hour at 4°C 
and then centrifuged at 5,000 rpm for 1 minute at 4°C. Agarose pellets were washed with 
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low salt wash buffer, high salt wash buffer, lithium chloride buffer, and TE buffer. Pellets 
were eluted with 1% SDS and 0.1 M NaHCO3. Five M (5 M) NaCl and RNase A were 
added, and crosslinks were reversed by incubating samples at 65°C for 4 hours. DNA 
was precipitated through addition of 100% ethanol, and samples were incubated 
overnight at -20°C. Samples were pelleted, resuspended in 100 µl water, 2 µl 0.5 M 
EDTA, 4 µl 1 M Tris pH 6.5, and 1 µl 20 mg/mL proteinase K, and then incubated for 
1.5 hours at 45°C. DNA was purified using QIAquick PCR Purification kit (Qiagen). 
PCR was performed with primers listed in Table 6.  All reactions contained: 1X Buffer B, 
1 µM of each primer, 2 µl DNA, and 1 U Taq DNA Polymerase (Fisher Scientific). 
Concentrations of MgCl2 and dNTP mix varied:  -41K, -6B, 6B, and +6B contained 1.5 
mM MgCl2 and 0.6 mM dNTP mix; 6A contained 2.0 mM MgCl2 and 0.6 mM dNTP 
mix; -40K, 5A, and 76K contained 2.5 mM MgCl2 and 0.4 mM dNTP mix; 5A contained 
2.5 mM MgCl2 and 0.8 mM dNTP mix. Reactions were run in an Eppendorf 
MasterCycler for 5 minutes at 94°C followed by 34 cycles of 30 seconds at 94°C, 30 
seconds at primer annealing temperature (see Table 6), and 30 seconds at 72°C. A final 
extension was carried out at 72°C for 10 minutes. Products were resolved on agarose 
gels.      
 
Bisulfite Sequencing  
Genomic DNA was isolated from HEK-293, HT-1080, SCC-25, and SK-N-SH 
cells using Wizard DNA Isolation kit (Promega Corp.). Conversion of unmethylated 
cytosines was done using the EpiTect® Bisulfite kit (Qiagen) according to the 
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recommended protocol. MethPrimer was used to analyze the COL4A5 and COL4A6 
promoter regions for presence of CpG islands and to design primers for bisulfite 
 
Table 6 Primers for ChIP analysis. Forward and reverse primer sequences to amplify regions of the 
COL4A5 and COL4A6 genes for ChIP analysis are shown. Primer annealing temperatures (Tm) are 
included. 
 
ChIP Product Forward Primer (5′-3′) Reverse Primer  (5′-3′) Tm
-6B GGGATGGTTAGAGGGTCAA GCAGAGCCCAGATGAGC 54°C 
6B GCTCATCTGGGCTCTGC CCATCTGTCTTATGTGGGAATA 54°C 
+6B TATTCCCACATAAGACAGATG ATATCTCCCATATAAAGACTTGA 50°C 
6A TATTTTCACATCTTCTGCTTGTA CTTTTCTATTCGTTCATTTGC 51°C 
5A GCAAATGAACGAATAGAAAAG GAGGGACAGTGAGGCTTG 52°C 
+5A CAAGCCTCACTGTCCCTC GCAAGCAGCCCTATTTTT 56°C 
-41K AGAAGATGT CCAAAACACACAG CACAAAGCCGTGAGCAAT 55°C 
-40K CTGGGTTTATGTTCTTAGATG CTGCCCTGGTTAATGGT 52°C 
76K GTCAGCAGGCAACAGGGA CTAACATCACAGATAAAAGAAGCAA 55°C 
 
 
sequencing (http://www.urogene.org/methprimer/). Two primer sets were used to analyze 
the COL4A5 and COL4A6 A promoter regions: BS1.1 (F 5′- 
GAAATTTTTTGTTTTGTGAGTAGTTG -3′), (R 5′- AACTCAATTCCAATCTCATTAATATAC -3′); 
BS1.2 (F 5′- TAATGAGATTGGAATTGAGTTTAGAAAA -3′), (R 5′- 
CCTCACCAACACAAAAAAATTTAA -3′). Two primer sets were used to evaluate 
methylation of the COL4A6 B promoter: BS2.1 (F 5′- 
AGTTATAATTTGAAATGGGAGGGAG -3′), (R 5′- AAACATCAACAAAACCCAAATAAAC -3′); 
BS2.2 (F 5′- GTGTTTTAAAGGGAAATAGGTTTAG -3′), (R 5′- 
 
 32
AAAATACCTAAAAATAAAAAAAACTACC -3′).  All reactions contained: 50 ng converted 
DNA, 1X Buffer B, 2.5 mM MgCl2, 0.6 mM dNTP mix, 1 µM of each primer, and 1 U 
Taq DNA Polymerase (Fisher Scientific). Reactions were run in an Eppendorf 
MasterCycler for 5 minutes at 94°C, 34 cycles of 30 seconds at 94°C, 30 seconds at 61°C 
(BS1.1, 1.2, and 2.2) or 63°C (BS2.1), 30 seconds at 72°C, followed by a final extension 
at 72°C for 10 minutes. PCR products were gel purified using QIAEX II Gel Extraction 
kit (Qiagen) and cloned into pCR4-TOPO (Invitrogen Corp.) following the 
manufacturer’s protocol. Ten clones for each primer set were sequenced using the 
BigDye Terminator kit and products were resolved on an ABI3100 automated sequencer 
(Applied Biosystems Inc.). DNA methylation patterns were analyzed using BiQ Analyzer 
(http://biq-analyzer.bioinf.mpi-sb.mpg.de/).          
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CHAPTER III 
RESULTS:  
THE ROLE OF CONSERVED, NON-CODING DNA IN TYPE IV COLLAGEN GENE 
REGULATION 
 
Characterization of Model Cell Lines 
 COL4A5 and COL4A6 are network-forming collagens that have been implicated 
in cancer metastasis and numerous other diseases. They have a unique genomic 
arrangement and exhibit tissue-specific expression patterns, thus regulation must be 
tightly controlled. To gain insight into how expression of this gene pair is modulated, an 
in vitro model system must be identified. Understanding what mechanisms account for 
differences in collagen expression in immortalized cell lines might shed light on in vivo 
gene regulation.    
Using qRT-PCR, four cell lines differing in type IV collagen gene expression 
were identified (see Figure 3A). COL4A6 primers used for this part of the study detected 
both transcript variants. COL4A5 and COL4A6 were both found to be expressed in SCC-
25 and HEK-293 cells, while SK-N-SH cells did not express either gene. HT-1080 cells 
selectively activated COL4A5. Relative expression of COL4A5 was approximately four 
fold higher in SCC-25 cells than HEK-293 cells (p < .0280). In SCC-25 cells, expression 
of COL4A5 was roughly 3.5 times greater than COL4A6 (p < .0152), while transcript 
levels were approximately equal in HEK-293 cells. 
In a separate set of experiments relative expression levels of COL4A6 transcript 
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Figure 3 Characterization of type IV collagen gene expression in model cell lines. (A), Relative 
expression levels of COL4A5 and COL4A6 were determined for SK-N-SH, HEK-293, HT-1080, and SCC-
25 cells using qRT-PCR. (B), Relative expression levels of COL4A6 transcript variants A and B were 
determined for SCC-25 and HEK-293 cells using qRT-PCR. *p < 0.05 
 
 
variants A and B were determined. For both HEK-293 and SCC-25 cells, COL4A6 B 
expression was higher than COL4A6 A. This relationship was only statistically significant 
in HEK-293 cells (p < .0038) (see Figure 3B). All four cell lines were shown to be unique 
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with respect to expression of COL4A5 and COL4A6, thus providing an appropriate in 
vitro model system with which to study collagen gene regulation. 
 
Evaluation of the Processing of Collagen Transcripts 
 There are three minimal promoters in just over a one kb segment of DNA, one for 
COL4A5 and two alternative promoters to transcribe COL4A6 (49). Because of the close 
proximity, recruitment of RNAPII and the transcription machinery to one promoter may 
affect transcription initiation at another. This is especially true for HT-1080 cells where 
COL4A5 was found to be selectively activated. Full length COL4A6 transcripts were not 
produced as determined by real time using primers specific to the 3′ end; however, it was 
unknown whether or not transcription was actually initiated at this site. Thus, primers 
targeting the 5′, middle, and 3′ portions of COL4A5 and COL4A6 transcripts were used to 
determine relative expression levels in all four cell lines. The results are displayed in 
Figure 4. COL4A6 transcripts were never detected in HT-1080 cells, suggesting that 
transcription was not initiated despite the presence of RNAPII nearby at the COL4A5 
promoter. In SK-N-SH cells, transcripts were not detected for any of the primer sets used. 
Transcription initiation of COL4A5 and COL4A6, therefore, appears to be followed by 
elongation and termination.  
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Figure 4 Evaluation of the processing of type IV collagen transcripts. qRT-PCR was used to determine 
relative expression levels of (A-C), COL4A5 and (D-F), COL4A6 for SK-N-SH, HEK-293, HT-1080, and 
SCC-25 cells using primer and probe sets targeting the (A, D), 5′, (B, E), middle, and (C, F), 3′ ends of the 
corresponding mRNA transcripts. Probes spanned exon-exon boundaries, as noted.      
 
 
Identification of Conserved, Non-Coding Sequences 
 Previous researchers have evaluated the COL4A5 and COL4A6 promoter regions 
using in vitro model systems (47,49). In addition, transgenic mice bearing regions of the 
collagen promoter have been generated to assess tissue-specific expression patterns (50). 
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Based on these experiments, it was concluded that the promoter region is insufficient to 
drive expression of COL4A5 and COL4A6 in a cell-type specific manner. It has been 
hypothesized that unidentified, cis-acting elements downstream of the promoter region 
are necessary for activation of transcription. Indeed, it has been shown that several non-
coding elements present in intronic DNA help control expression of other type IV 
collagen genes (42).  
 Each type IV collagen gene is over 200 kb in length, with the majority of the 
sequence representing intronic DNA. For example, the first intron in COL4A5 is 
approximately 100 kb (87). Consequently, efforts to identify sequences that are involved 
in gene regulation have been hindered. In recent years, researchers have experienced 
success in utilizing comparative genomics to narrow the search for regulatory DNA. This 
is based on the premise that conserved DNA is selectively constrained and, therefore, 
thought to be functional (76-79). For the current study, the comparative genomics 
approach was deemed appropriate and used for the identification of putative regulatory 
elements involved in collagen regulation.  
Human COL4A5 and COL4A6 genomic sequences were aligned to the genomes 
of 13 other species. Approximately 260 kb of COL4A5 and the first 50 kb of COL4A6 
were evaluated. Because previous evidence exists to suggest that distal regulatory 
elements selectively activate COL4A5, the entire gene was included for analysis. The 
most current human genome sequence was used for alignment; however, since the time of 
analysis, this sequence has been updated and additional vertebrate sequences are now 
available.  
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A total of 38 sequences were identified as being conserved between the human 
reference and at least one other vertebrate using the established criteria of ≥ 70% 
homology and ≥ 100 bp. Of these, 13 conserved sequences overlapped exons of COL4A5; 
no sequences overlapped COL4A6 exons. The remaining 25 conserved segments did not 
align with any cDNA sequences and are, therefore, likely to represent non-coding 
regions.     
To prioritize a set of conserved, non-coding sequences, those regions conserved 
between the human and three or more non-primate vertebrates were chosen to be tested 
for ability to regulate gene expression in vitro. A total of 17 regions fit the criteria. 
Primers were designed to amplify each conserved, non-coding sequence individually with 
the exception of -43K and -110. Both primer sets were able to capture two sequences. 
The boundaries that define these conserved regions are not well-defined; therefore, to 
help ensure that all significant elements were captured, each forward and reverse primer 
was at least 25 bp upstream and downstream, respectively, of the conserved, non-coding 
sequence. Figure 5 displays the relative locations of conserved sequences.   
Each region was cloned into the pGL3-promoter vector in the orientation of the 
gene in which it is located. Five conserved, non-coding sequences present in COL4A6 
were also cloned in the COL4A5 direction. Additionally, a primer set was designed to 
amplify a non-conserved, non-coding sequence to assess how a random segment of DNA 
would behave. The pGL3-promoter vector was chosen so that, in addition to activators, 
repressor elements could be identified. Each sequence was transfected into all four cell 
lines and tested for the ability to regulate expression of the reporter gene in a cell-type 
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specific manner. Results are displayed in Figure 6. Activity of the pGL3-promoter vector 
was arbitrarily set at 100%, and conserved, non-coding sequences were graphed as % 
pGL3-promoter. Constructs with % pGL3-promoter activities above 100% were believed 
to have increased transcription of the reporter gene, whereas values below 100% 
represent inhibition of transcription. Constructs with % pGL3-promoter activities near 
100% were said to have no effect on transcription. 
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Figure 5 Relative locations of conserved, non-coding sequences in COL4A5 and COL4A6. The relative 
locations of the 15 conserved sequences as well as the non-conserved, non-coding sequence are shown. 
Each sequence was named based on the relative location with respect to the COL4A5 transcription start site. 
 
 
In Vitro Analysis of the COL4A5-COL4A6 Promoter 
The pα6(-110) and pα5(-110) constructs represent conserved, non-coding DNA in 
the promoter region near the COL4A5  and COL4A6 A TSSs. Percent pGL3-promoter 
activity of pα6(-110) was relatively unchanged in SK-N-SH, HT-1080, and SCC-25 cell 
lines. In HEK-293 cells, transcription was repressed with a % pGL3- promoter value of 
51%. In the α5 direction, the COL4A5-COL4A6 promoter activated transcription in only 
SK-N-SH cells with a % pGL3-promoter value reaching 191%. Expression of the 
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reporter gene remained relatively unchanged in HT-1080 cells and was decreased in 
HEK-293 and SCC-25 cells; % pGL3-promoter values were 115%, 58%, and 58%, 
respectively. Results are displayed in Figure 6A.  
The DNA segment cloned upstream of the reporter gene in pα6(-110) and pα5(-
110) included the CCAAT and CTC boxes present in the COL4A5-COL4A6 promoter 
region. Figure 1 is a diagram of the relative locations of these motifs. Approximately 340 
and 230 bp upstream and downstream, respectively, of the COL4A5 TSS were captured. 
With respect to COL4A6 A, 520 and 50 bp upstream and downstream, respectively, were 
included in these constructs.  Despite inclusion of TF binding sites and almost 600 bp of 
the promoter region, neither construct could significantly enhance transcription in HT-
1080, HEK-293 or SCC-25 cells. It can be concluded, therefore, that elements outside of 
this region are required for efficient transcription in these cell types. In addition, distal-
acting elements may be necessary as has been previously shown for cell types selectively 
expressing COL4A5. The possibility also exists that the SV40 promoter in the pGL3 
vector negatively interfered with the COL4A5-COL4A6 promoter. To resolve this, the 
collagen promoter should be cloned into a promoter-less vector and tested in transfection 
experiments. Finally, it is important to mention that the only cell type where the promoter 
exhibited activity was SK-N-SH cells in which neither gene was found to be transcribed. 
Although these results were unexpected, it is unlikely that the promoter is truly active 
when put in the context of chromatin. 
 SK-N-SH HEK-293 HT-1080 SCC-25
Luciferase/Renilla Activity (% pGL3-Promoter)
pα6(-43K)
pα6(-41K)
pα6(-40K)
pα6(-25K)
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A 
Figure 6 Percent pGL3-promoter activity of conserved, non-coding sequences. Conserved sequences were cloned into the pGL3-promoter vector 
in the COL4A6 (pα6) and COL4A5 (pα5) directions and transfected in to SK-N-SH, HEK-293, HT-1080, and SCC-25 cell lines. The % pGL3-promoter 
activity is shown for (A), conserved, non-coding sequences located in COL4A6, the promoter, and COL4A5 as well as (B), conserved sequences located 
in COL4A6, but cloned into the vector in the α5 direction. In addition, promoter activities for six constructs containing conserved regions deep within 
COL4A5 are displayed. Luciferase activities represent mean +/- S.E. (n = 3).    
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In Vitro Analysis of Conserved, Non-Coding Sequences 
Constructs that exhibited differences in activity across cell types were identified 
and considered to be potentially significant in collagen regulation. Of the four pα6 
constructs, only pα6(-41K) showed differences among cell types. The % pGL3-promoter 
activity of pα6(-41K) was decreased in HEK-293 cells (36%) and moderately increased 
in SCC-25 cells (123%). The pα6(-41K) construct had larger effects on transcription in 
SK-N-SH and HT-1080 cells with an increased activity of 144% and 187%, respectively. 
See Figure 6A. When pα6(-28K) was transfected into SCC-25 cells, the normalization 
vector did not exhibit activity levels above background, thus RLUs were unable to be 
calculated. For some unknown reason, these two vectors interacted to negatively impact 
transcription of the normalization vector; therefore, data from pα6(-28K) was not 
included for analysis. 
The pα5(16K), pα5(21K), and pα5(25K) constructs did not exhibit cell-type 
specific differences. On the other hand, transcription was significantly increased when 
pα5(76K) was transfected into SK-N-SH and HT-1080 cells. The % pGL3-promoter 
activity reached 403% and 381%, respectively. Expression of the reporter gene decreased 
in HEK-293 and SCC-25 cells; % pGL3-promoter values were 48% and 77%, 
respectively. These results are shown in Figure 6A.  
 Conserved, non-coding elements in COL4A6 were also cloned into the reporter 
vector in the COL4A5 orientation; cis-acting DNA in COL4A6 can also interact with the 
COL4A5 promoter. Of the five constructs, two exhibited cell-type specific differences. In 
HT-1080 cells, the pα5(-41K) construct increased transcription by 50% over the empty 
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pGL3-promoter vector. The same results were seen for this construct in SCC-25 cells 
with a % pGL3-promoter activity of 225%. Transcription of the reporter gene was 
repressed in SK-N-SH and HEK-293 cells; % pGL3-promoter activity was 70% and 
39%, respectively. The pα5(-40K) construct moderately decreased expression in all cell 
types except for SCC-25 cells where % pGL3-promoter activity reached 193% (Figure 
6B).  
 An additional six constructs containing conserved elements in COL4A5 were 
assessed for the ability to affect transcription. Surprisingly, none of these constructs 
displayed differences among cell types. See Figure 6B.   
In addition to determining which constructs exhibited cell-type specific 
differences, the activity of all constructs within a cell type was assessed. For each cell 
line, % pGL3-promoter values for the majority of constructs fell within a particular 
range. For constructs within this range, therefore, the effects on transcription appear to be 
independent of the conserved, non-coding DNA transfected. The range for SK-N-SH and 
SCC-25 cells was approximately 50-90%, while the ranges for HT-1080 and HEK-293 
cells were roughly 60-90% and 35-75%, respectively.   
Constructs within these ranges were not investigated at this time, which included 
pα6(-41K), pα5(76K), pα5(-41K), and pα5(-40K) in HEK-293 cells and pα5(-41K) and 
pα5(-40K) in SK-N-SH cells. In HT1080 cells, pα5(-40K) was excluded for further 
analysis. The pα6(-41K) and pα5(76K) constructs did not appear to be important in SCC-
25 cell lines. Significantly, the non-coding, non-conserved DNA segment, pα5(-16K), fit 
into this category, thus providing support for this method of analysis. It is important to 
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mention that this is not a fail-proof way to identify putative regulatory elements. The 
criteria used in this study to narrow the search are only a starting point, and the remaining 
conserved, non-coding elements should be investigated in the future.  
 The constructs that may contain functional DNA elements are pα6(-41K), 
pα5(76K), pα5(-41K), and pα5(-40K). The pα6(-41K) and pα5(76K) constructs enhanced 
transcription of the reporter gene in both SK-N-SH and HT-1080 cell lines. These 
elements could potentially activate transcription of COL4A5 in HT1080 cells; however, 
their role in SK-N-SH cells is less clear. Significantly, in HT-1080 cells -41K also 
operated in the COL4A5 direction as pα5(-41K) was shown to increase reporter gene 
activity. In SCC-25 cells, pα5(-41K) and pα5(-40K) were shown to enhance transcription, 
thus providing evidence to suggest that these elements could potentially activate COL4A5 
and/or COL4A6.  
General conclusions can be drawn from this data. First, these functional 
constructs contain transcription factor binding sites. In the cell types in which the 
constructs function, transcription factors are available to bind to their recognition 
sequences and interact with the SV40 promoter to facilitate transcription. It can not be 
determined, however, whether or not these elements are functional when in their native 
chromatin environment. Additional studies will have to be carried out to assess this.  
  Surprisingly, only a few of the 21 different constructs evaluated in this study 
appear to be potentially functional. Previous experiments done using this type of assay 
system showed that the majority of conserved, non-coding sequences tested were able to 
exhibit cell-type specific differences (84,85). There are several possibilities that exist to 
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help explain the observed inconsistencies between the current and previous studies. In the 
current study, amplicon sizes of conserved, non-coding sequences were much smaller 
than those used in other experiments. Perhaps other regulatory elements nearby the 
conserved regions exist and were not captured in this study. Alternatively, the effects 
seen on transcription in the previous studies could be non-specific, i.e. resulted from 
random transcription factor binding sites that are likely to exist over several kb of DNA. 
In addition, the utilization of different vector constructs may affect results. This study 
used a vector with a promoter, while other studies have used the native promoter or 
promoter-less vectors.  
 As mentioned previously, constructs excluded from further analysis should be re-
evaluated in the future. It is possible that these sequences act in concert with one another 
to activate or repress transcription of COL4A5 and/or COL4A6. More insight can also be 
gained from placing these conserved, non-coding elements next to the native promoter 
and assessing how transcription is affected in different cell types. Nevertheless, initial 
analyses have provided a basis for future studies.  
 
Evaluation of Histone Acetylation of Conserved, Non-Coding Sequences 
 Genome-wide acetylation patterns were recently mapped in human T cells. Gene-
rich regions were found to be associated with the highest levels of histone acetylation, 
although acetylation across euchromatin domains was not uniform. Instead, 
hyperacetylated regions co-localized with active promoters as well as conserved, non-
coding sequences thought to be biologically significant. In addition, these “acetylation 
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islands” co-localized with regulatory elements known to function in T cells. The authors 
concluded that acetylation of cis-acting elements prevents the spreading of 
heterochromatin and promotes an open chromatin structure to allow transcription factors 
to bind (56).  
Based on the data summarized above, ChIP analysis was used to determine the 
acetylation state of the conserved, non-coding sequences identified in COL4A5 and 
COL4A6. Antibodies directed against acetylated histone H3 were used to 
immunoprecipitate SCC-25, SK-N-SH, HEK-293, and HT-1080 chromatin. Primers were 
designed to amplify regions spanning -41K, -40K, and 76K; acetylation patterns were 
assessed in all four cell lines, and the results are displayed in Figure 7.    
Both pα5(-41K) and pα5(-40K) constructs significantly enhanced transcription of 
the reporter gene in SCC-25 cells. ChIP analysis revealed the association of acetylated 
histone H3 with -41K and -40K as evidenced by the ability to amplify these DNA 
regions. In HT-1080 cells, acetylated histones were also associated with 76K and -41K, 
which was shown to function in both directions. According to this data, these conserved 
sequences are correlated with acetylated histones, thus providing additional evidence to 
support their role in activation of COL4A5 and/or COL4A6. 
In SK-N-SH cells, -41K and 76K were associated with acetylated histones. 
Because neither COL4A5 nor COL4A6 was transcribed in this cell line, it is unlikely that 
these conserved sequences are functional with regards to gene activation. Each cell type 
is independent of the other, thus these data do not negate the potential functional role of -
41K and 76K in SCC-25 and HT-1080 cells.  
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Figure 7 Chromatin immunoprecipitation analysis of conserved, non-coding sequences. ChIP analysis 
was used to determine the histone acetylation state of the conserved, non-coding sequences -41K, -40K, 
and 76K. Acetylation patterns were assessed in SK-N-SH, HEK-293, HT-1080, and SCC-25 cell lines. 
 
 
Acetylated histones were also associated with other conserved sequences that did 
not appear to be functional in the cell-based assay including -41K in HEK-293, -40K in 
HT-1080, and 76K in SCC-25 cells. Consequently, transfection data was re-evaluated. In 
HEK-293 cells, -41K appears to be repressing transcription of the reporter gene more 
than what was considered to be average in this cell type. The % pGL3-promoter activities 
for pα6(-41K) and pα5(-41K) were 36% and 39%, respectively. Significantly, these were 
the two lowest values obtained in HEK-293 transfections. It can be argued, therefore, that 
acetylation patterns can aid in identifying functionally significant elements that may be 
missed otherwise. In addition, the association of acetylated histones with -40K and 76K 
in HT-1080 and SCC-25 cells, respectively, merits further investigation.  
 In summary, strong evidence exists to support the functional role of -41K and 
76K in HT-1080 cells, -41K and -40K in SCC-25 cells, and -41K in HEK-293 cells. 
These sequences were shown to 1) be highly conserved across numerous species, 2) 
affect transcription of a reporter gene in a cell-based assay, and 3) be associated with 
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acetylated histone H3. Further experiments should be executed to further delineate their 
role in transcription of COL4A5 and COL4A6. 
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CHAPTER IV 
RESULTS: 
THE ROLE OF EPIGENTIC MODIFICATIONS IN TYPE IV COLLAGEN GENE 
REGULATION 
  
 Eukaryotic cells mediate changes in gene expression by altering chromatin 
structure and interactions between the transcription machinery and DNA. Epigenetic 
marks including histone modifications and DNA methylation are intimately involved in 
this process. To determine the role epigenetics play in modulating expression of 
collagens, three sets of experiments on all four cell lines were carried out: 1) cells were 
treated with epigenetic modifying agents and the effect on expression of COL4A5 and 
COL4A6 was measured, 2) ChIP analysis was used to assess the chromatin structure 
surrounding the collagen promoter, and 3) the methylation status of CpG dinucleotides in 
the collagen promoter region was determined using bisulfite sequencing.  
 The COL4A5-COL4A6 gene pair is located on the X chromosome. Consequently, 
the mechanism of X chromosome inactivation and the number of X chromosomes in each 
cell line must be considered when analyzing data from these experiments. Random X 
chromosome inactivation involves association of Xist, an untranslated RNA molecule, 
with the inactive X. Coating of the inactive X chromosome with Xist transcripts is then 
followed by histone modifications that facilitate heterochromatin formation and DNA 
methylation. The inactive X is also associated with late replication timing and is localized 
to the nuclear periphery to ensure a silenced state (88).  
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 Based on cytogenetic analyses, SCC-25 cells were shown to have one X 
chromosome, HT-1080 cells consisted of XY, SK-N-SH cells contained two X 
chromosomes, and HEK-293 cells were associated with three X chromosomes 
(http://www.atcc.org). Because of dosage compensation, it can be assumed that in each 
cell only one X chromosome was active; this is true for all four cell lines.   
 
Type IV Collagen Response to Epigenetic Modifying Agents 
 SK-N-SH, HEK-293, HT-1080, and SCC-25 cells were treated with TSA, 5-Aza, 
and a combination treatment of TSA plus 5-Aza. TSA inhibits HDAC activity, thereby 
forcing acetylation of histones, while treatment with 5-Aza results in global 
demethylation of CpG dinucleotides. Response to treatment was assessed using qRT-
PCR and primers targeting the COL4A5 or COL4A6 transcripts; the COL4A6 primers 
used did not discriminate between the transcript variants. 
Any changes in gene expression in HT-1080 and SCC-25 cells were the result of 
epigenetic modifying agents acting on the single active X chromosome. The same is true 
for SK-N-SH and HEK-293 cells despite the fact that more than one X chromosome was 
present. In other words, it is unlikely that treatment with TSA or 5-Aza alone will affect 
expression of the collagen genes present on the inactive X chromosome. As outlined 
above, several layers of repression are responsible for keeping the inactive X in a 
silenced state. Results for each cell line are displayed in Figure 8.      
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SK-N-SH  
 Neither collagen gene was transcribed under normal conditions in SK-N-SH cell 
lines. Treatment with TSA dramatically increased expression of COL4A5 and COL4A6 
approximately 16- and 7.7-fold, respectively. Relative expression of both genes slightly 
increased upon treatment with 5-Aza, although the effects were certainly not as dramatic 
as what was seen after TSA treatment; fold changes for COL4A5 and COL4A6 were 2.9 
and 1.6, respectively. Finally, expression of both genes increased upon combination 
treatment; a 34-fold increase for COL4A5 and a 9.9-fold increase for COL4A6 were seen. 
This increase appears to be synergistic, especially for COL4A5; perhaps the combined 
treatment was enough to relieve repression of the collagen genes on the inactive X 
chromosome. Results are displayed in Figure 8A.  
Based on these observations, repression of COL4A5 and COL4A6 appears to be 
mediated through chromatin structure. More specifically, forced acetylation was enough 
to de-repress both genes, suggesting that an unidentified repressive complex operates to 
support a tightly packed chromatin structure that involves the removal of acetyl groups 
from histones. Moreover, repression appears to be independent of DNA methylation as 
treatment with 5-Aza had little effect on expression levels. 
 
SCC-25 
 Although COL4A5 and COL4A6 were shown to be actively transcribed in SCC-
25 cells, expression of both transcripts increased slightly upon treatment with 5-Aza. The 
relative fold changes as compared to the control were approximately 2.5 and 3.8 for 
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Figure 8 Type IV collagen gene expression following treatment with epigenetic modifying agents. (A), SK-N-SH, (B), HEK-293, (C), HT-1080, 
and (D), SCC-25 cell lines were treated with 5-Aza, TSA, and 5-Aza plus TSA. Relative expression levels of COL4A5 and COL4A6 were determined 
using qRT-PCR. 
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COL4A5 and COL4A6, respectively. Treatment with TSA resulted in a slight increase in 
fold change of COL4A6 (1.8), which may reflect complete de-repression. Expression of 
COL4A5 was unchanged following treatment with TSA suggesting that histones in this 
area may already be fully acetylated. Combined treatment resulted in a moderate increase 
in fold changes for both genes; COL4A5 and COL4A6 fold changes were 2.5 and 3.7, 
respectively. Results are presented in Figure 8D.  
These data taken together suggest that under normal growth conditions in SCC-25 
cells, histones associated with the collagen promoter are in the acetylated state to promote 
transcription. DNA methylation may act to repress collagen expression in a sub-
population of cells, although it is possible that the slight increase in expression following 
treatment resulted from an indirect effect, i.e. change in expression at another locus. 
More experiments are necessary to determine the role, if any, of DNA methylation in this 
cell type.  
 
HEK-293 
 HEK-293 cells were shown to produce both transcripts, thus the effects on 
expression following treatment with epigenetic modifying agents were only moderate. In 
fact, the general trends resembled those seen for SCC-25 cells. Relative fold changes of 
COL4A5 and COL4A6 increased approximately 2.4- and 2.2-fold, respectively, following 
treatment with 5-Aza. Whether or not this slight increase reflects actual methylation of 
DNA at the collagen promoter under normal conditions can not be determined from this 
data; however, further investigation is warranted. TSA treatment resulted in a roughly 2-
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fold increase in expression of both COL4A5 and COL4A6, which is, again, most likely 
due to complete de-repression.  
 Relative fold change of COL4A6 increased approximately 1.6 upon combination 
treatment, while COL4A5 was unchanged. Based on the trends observed for treatment 
with 5-Aza or TSA alone, increased expression would be expected following 
combination treatment. This lack of increase may be a result of toxicity leading to cell 
death. See Figure 8B for results.   
These data support the hypothesis that histone acetylation or DNA demethylation 
alone is not enough to activate collagens on the inactive X chromosome. Because there 
are two inactive X chromosomes in HEK-293 cells, a much larger increase in expression 
following treatment would be expected. 
 
HT-1080 
 In HT-1080 cells, relative fold changes of COL4A5 compared to the control did 
not increase after treatment with 5-Aza, TSA, or 5-Aza plus TSA. It does not appear, 
therefore, that DNA methylation affects expression of COL4A5; the lack of increase in 
expression following treatment with TSA may reflect fully acetylated histones in this 
area. Significantly, combination treatment and 5-Aza alone resulted in a 7.6- and 8.2-fold 
increase, respectively, in COL4A6 expression. No change was seen following treatment 
with TSA. These results suggest that DNA methylation plays a role in repression of 
COL4A6 that is independent of histone acetylation. Results are shown in Figure 8C.     
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Chromatin Immunoprecipitation Analysis of COL4A5-COL4A6 Promoter 
 ChIP analysis allows the relationship between a particular protein and DNA to be 
determined. Histone modifications as well as DNA-bound proteins can be assessed using 
this technique. Antibodies directed against RNAPII, acetylated histone H3, and dimethyl 
histone H3K9 (H3K9me2) were used in the current study to look at DNA surrounding the 
COL4A5 and COL4A6 promoters. In addition, antibodies against HP1 were used in SK-
N-SH cells because of the established association between HP1 and the silencing of 
genes in euchromatin. Acetylated histone H3 correlates with open chromatin that is 
favorable for transcription, while H3K9me2 targeted to the promoter region of genes is 
associated with repression. These two antibodies, therefore, were deemed to be 
appropriate markers to assess the role of chromatin in modulating collagen expression. 
Significantly, in SK-N-SH and HEK-293 cells ChIP analysis does not distinguish 
between the active and inactive X chromosomes; this fact must be considered when 
analyzing results.  
 ChIP analysis can determine the position of a protein along a stretch of DNA 
based on relative amounts of enrichment seen for overlapping primer sets. The most 
accurate method to quantify enrichment is qRT-PCR. Standard PCR can also be used; 
however, this technique is only semi-quantitative. The current study used PCR, thus 
determination of the precise location of a modification or protein binding was not 
attempted. Locations of primer sets used in this study are displayed in Figures 9A and 
10A. ChIP results can be found in Figures 9B, C and 10B, C and Table 7 summarizes 
these findings. 
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Table 7 Summary of chromatin immunoprecipitation analysis of the COL4A5-COL4A6 promoter. 
Results of ChIP analysis for SK-N-SH, HEK-293, HT-1080, and SCC-25 cell lines are summarized. 
Positive and negative associations are designated as + and -, respectively.  
 
 
SK-N-SH +6B 6B -6B 6A 5A +5A HEK-293 +6B 6B -6B 6A 5A +5A 
H3K9me2 + + + + + + H3K9me2 + + + + + + 
RNAPII - - - - - - RNAPII + + + + + + 
AcH3 - - - - - - 
 
AcH3 + + + + + + 
 
HT-1080 +6B 6B -6B 6A 5A +5A SCC-25 +6B 6B -6B 6A 5A +5A 
H3K9me2 + + + + - + H3K9me2 + + + - - - 
RNAPII - - - + + + RNAPII + + + + + + 
AcH3 + + - + + + 
 
AcH3 + + + + + + 
 
SK-N-SH 
 The entire promoter region was found to be associated with H3K9me2 in SK-N-
SH cells as evidenced by the presence of PCR bands for all primer sets. Enrichment of 
RNAPII and acetylated histone H3 was not seen. Results are presented in Figures 9B and 
10B. In addition, PCR bands for HP1 were present using primers 6B and +5A, whereas 
no products were produced with the remaining primer sets (see Figures 9C and 10C). 
This suggests HP1 may be involved in silencing both genes, perhaps through associations 
with H3K9me2 at distinct locations; the possibility also exists that enrichment resulted 
from the association of HP1 with the inactive X. Indeed, HP1 has been shown to be 
involved in heterochromatin formation of the inactive X chromosome through binding 
methyl H3K9 (89). Nonetheless, these findings suggest that the collagen promoter is in a  
 
 58
 
 
Figure 9 Chromatin immunoprecipitation analysis of COL4A5 and COL4A6 A promoters. (A), 
Relative locations of primer sets used to analyze COL4A5 and COL4A6 A regions are shown. ChIP analysis 
using antibodies against (B), RNAPII, H3K9me, and acetylated histone H3 (AcH3) was carried out in SK-
N-SH, HEK-293, HT-1080, and SCC-25 cell lines. In addition, (C), HP1 was used in SK-N-SH cells.  
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Figure 10 Chromatin immunoprecipitation analysis of COL4A6 B promoter. (A), Relative locations of 
primer sets used to analyze the COL4A6 B region are shown. ChIP analysis using antibodies against (B), 
RNAPII, H3K9me, and acetylated histone H3 (AcH3) was carried out in SK-N-SH, HEK-293, HT-1080, 
and SCC-25 cell lines. In addition, (C), HP1 was used in SK-N-SH cells. 
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closed chromatin state that is important in preventing RNAPII and the transcription 
machinery from binding to initiate transcription.  
 
HEK-293 
 In HEK-293 cells, the COL4A5 and COL4A6 promoter region was found to be 
associated with RNAPII, acetylated histone H3, and H3K9me2; all six primer sets 
produced PCR products for each antibody. Results are displayed in Figures 9B and 10B.  
 RNAPII and acetylated histone H3 were most likely only associated with the 
active X chromosome during transcription of both collagen genes. Histone H3K9me2 
was probably associated with the inactive X chromosomes, but this modification could 
also be present on histones surrounding the collagen promoter on the active X. In the 
population as a whole at any given moment, it is unlikely that every single cell was 
actively transcribing COL4A5 and COL4A6. It has been previously shown that when 
transcription is not re-initiated, histones are modified to facilitate formation of closed 
chromatin. This prevents cryptic initiation and provides a mechanism to control the rate 
of transcription (65). Therefore, enrichment of H3K9me2 may be correlated with the 
inactive and well as the active X chromosomes; association with the active X reflects 
cells in different stages of transcription. 
 
HT-1080 
 HT-1080 cells were characterized by a unique pattern of enrichment, most likely 
reflecting activation of only COL4A5. Results are shown in Figures 9B and 10B. RNAPII 
 
 61
was found to be associated with COL4A5 and COL4A6 A promoters, as evidenced by 
PCR products obtained using 6A, 5A, and +5A primer sets. COL4A6 transcripts were not 
produced in this cell type, thus association of RNAPII with the COL4A6 A promoter may 
be a result of limited resolution. When chromatin was immunoprecipitated with 
H3K9me2, all primer sets generated products except for 5A, which spans the COL4A5 
TSS. Acetylated histone H3 was found to be associated with the entire promoter region 
except for the area captured by the -6B primer set; the intensity of the product was equal 
to that produced by IgG, which is suggestive of non-specific pull-down. Lack of histone 
acetylation at DNA surrounding -6B suggests that this region is important in preventing 
transcription of COL4A6 A and B, whereas lack of H3K9 methylation at COL4A5 TSS 
may be necessary to keep chromatin open for transcription initiation.  
 
SCC-25 
 Following immunoprecipitation of SCC-25 chromatin, PCR revealed the presence 
of RNAPII across the COL4A5 and COL4A6 promoters. Acetylated histone H3 was also 
found to be associated with this region as PCR products were obtained for all primer sets. 
These results are indicative of active transcription of both genes. Significantly, products 
were present only using primer sets +6B, 6B, and -6B following immunoprecipitation 
with H3K9me2. Enrichment of H3K9me2 was not found surrounding COL4A5 and 
COL4A6 A promoters, suggesting that differences in transcription rates exist. See Figures 
9B and 10B for results.   
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Analysis of DNA Methylation in COL4A5-COL4A6 Promoter 
 Treatment of cell lines with the epigenetic modifying agent 5-Aza provided 
evidence to suggest that DNA methylation may play a role in repression of collagen 
expression. To investigate this further, bisulfite sequencing of the entire promoter region 
was carried out to determine the methylation status of CpG dinucleotides. The results are 
presented in Figure 11.  
Based on the established criteria, MethPrimer failed to detect CpG islands in the 
COL4A5 and COL4A6 promoter regions. Nevertheless, bisulfite sequencing was carried 
out. Four primer sets were used to capture the majority of CpGs in the area. BS1.1, 
BS1.2, BS2.1, and BS2.2 captured 4, 7, 15, and 3 CpG dinucleotides, respectively. CpGs 
are concentrated in the area encompassed by the BS2.1 primer set. See Figure 11A.   
 In SCC-25 cells, methyl CpGs were sparse making it very unlikely that DNA 
methylation plays a functionally significant role. A relatively fair amount of methyl CpGs 
were present across the entire promoter region in HEK-293 cells. DNA was also 
methylated in SK-N-SH cells, although not as many methyl CpGs were detected as 
compared to HEK-293 cells; complete absence of DNA methylation was seen for the 
region captured by the BS1.1 primer set. These findings most likely reflect methylation 
of the promoter region on the inactive X chromosomes. The presence of methyl CpGs for 
each amplicon would be expected if both the active and inactive chromosomes were 
associated with DNA methylation. Amplification of the entire promoter region in fewer 
primer sets would be helpful as this would allow the methylation profile of a contiguous 
piece of DNA to be assessed.
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Figure 11 DNA methylation profiles of the COL4A5-COL4A6 promoter as determined by bisulfite sequencing. (A), Relative locations of primer 
sets used to determine the methylation status of CpG dinucleotides in (B), SK-N-SH, HEK-293, HT-1080, and SCC-25 cell lines; open circle, CpG; 
filled circle, methyl CpG.
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DNA surrounding the COL4A6 B promoter region was found to be heavily 
methylated in HT-1080 cells (see results for primer sets BS2.1 and BS2.2 presented in 
Figure 11B). This observation, along with absence of methylation at the COL4A5 
promoter, provides strong evidence to suggest that methylation of CpGs plays a 
functional role in silencing expression of the COL4A6 B transcript. Significantly, the 
COL4A6 A promoter region was free of methyl CpGs (see results for primer set BS1.1). 
The question then becomes how do HT-1080 cells repress transcription of COL4A6 A? 
The possibility exists that methylation of the B promoter indirectly affects expression at 
the A promoter; however, other mechanisms may also be at work in this cell line.     
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CHAPTER V 
CONCLUSION 
 
Regulation of Type IV Collagen Genes Occurs at Transcription Initiation 
 In a recent study scientists reported that, contrary to what has previously been 
known, the majority of protein-coding genes in human cells experience transcription 
initiation; the promoter region of this class of genes is characterized by histone 
modifications associated with active transcription and the presence of RNAPII, although 
full length mRNA transcripts are undetectable. Additionally, these genes lack markers 
correlated with elongation, suggesting that regulation occurs post-transcription initiation 
(90).  
The study reported herein provides evidence that, although the majority of genes 
may experience transcription initiation, type IV collagens do not fit into this category. 
Presence of RNAPII and full length transcripts were detected only when COL4A5 and/or 
COL4A6 were actively being transcribed. In SK-N-SH cells RNAPII was absent across 
the entire promoter region, and neither collagen transcripts were detected even when 
primers targeting the 5′ ends were used. The same results were seen for HT-1080 cells 
with respect to COL4A6. These findings corroborate previous research (49). Moreover, 
epigenetic modifications discussed in the following sections maintain the view that 
regulation of collagens occurs at transcription initiation.  
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Activation of COL4A5 and COL4A6 in SCC-25 and HEK-293 Cells 
 According to real time data, COL4A5 and COL4A6 A and B transcripts were 
expressed in SCC-25 and HEK-293 cell lines. As expected for genes being actively 
transcribed, ChIP assays revealed the presence of RNAPII and acetylated histone H3 
across the promoter region. A model is proposed for regulation of this gene pair in SCC-
25 and HEK-293 cells based on these observations and what is currently known about 
mechanisms for gene activation (see Figure 12) (51,52). Briefly, in the absence of 
binding of the bi-directional activator, which has been shown to be necessary for bi-
directional transcription of COL4A5 and COL4A6, both genes are silent (49). The bi-
directional activator binds to the promoter region in response to a stimulus and functions 
to recruit chromatin remodelers and HATs. As a result, nucleosomes become more 
mobile and contacts between DNA and histones are loosened, thus allowing for 
components of the PIC to assemble. Finally, RNAPII is recruited and transcription is 
initiated.  
This is a simplified view, as it is likely that other transcription factors bind 
upstream of both promoters and interact with the bi-directional activator and PIC 
components to recruit necessary players. Two conserved, non-coding sequences, -41K 
and -40K, were shown to activate transcription of a reporter gene in SCC-25 cells and 
were also found to be associated with acetylated histone H3. These sequences may 
contain functional elements necessary for expression of COL4A5 and/or COL4A6 in 
SCC-25 cells. In addition to activators, repressor complexes may act to alter expression 
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of collagen genes. The -41K construct repressed transcription in HEK-293 cells and may 
be functional in vivo.  
 
 
 
 
Figure 12 Proposed model for activation of collagen genes in SCC-25 and HEK-293 cells. COL4A5 
and COL4A6 are silent in the absence of the bi-directional activator. Upon binding, the activator functions 
to recruit chromatin remodelers and HATs. Histone tails become acetylated allowing for formation of PIC 
and subsequent transcription initiation. See text for more details. BA, bi-directional activator; BAE, bi-
directional activator element; Ac, acetyl group. 
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 The model for activation presented above does not depict the apparent differences 
seen in expression of collagens as determined by real time. Differences in COL4A5 will 
be addressed here, and the COL4A6 transcript variants will be discussed in the following 
section.  
Relative expression of COL4A5 in SCC-25 cells was approximately four times 
that which was seen in HEK-293 cells. This finding may be a result of differences in 
transcription rates; evidence to support this comes from ChIP analysis and treatment data. 
As mentioned previously, acetylation of histone tails is directly correlated with the 
amount of transcription, whereas methylation of histone H3K9 is associated with closed 
chromatin. In HEK-293 and SCC-25 cells, the only region that was found to not be 
associated with H3K9me2 was the COL4A5 promoter in SCC-25 cells. This suggests that 
transcription is continuously initiated and explains the higher expression levels seen in 
SCC-25 cells. Moreover, upon treatment with the HDAC inhibitor, TSA, COL4A5 
expression levels were unchanged in SCC-25 cells, thus supporting the view of fully 
acetylated histones. In contrast, forced acetylation did increase expression of both 
collagens in HEK-293 cells and COL4A6 in SCC-25 cells approximately two-fold as 
compared to the control. These data taken together support the idea that expression levels 
correlate with histone modifications and transcription initiation. Although these data 
correlate nicely, post-transcription mechanisms of regulation may still contribute to 
steady state transcript levels.      
It is important to mention that gene activation is not necessarily a direct result of 
histone modification. Instead, it is more likely that an upstream stimulus, i.e. binding of 
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the bi-directional activator, mediates its effects through changes in chromatin structure. 
So, what upstream signal accounts for differences in expression of COL4A5 and what is 
the functional consequence of this? This will certainly be of interest when studying 
collagen expression in the future.  
 
COL4A6 Transcript Variants 
The COL4A6 transcript variants A and B differ only in their signal peptide 
sequences, the functional significance of which is currently unknown (48). In both SCC-
25 and HEK-293 cells the relative expression of COL4A6 B was higher than COL4A6 A, 
although only statistically significant in HEK-293 cells. The chromatin environment 
surrounding the COL4A6 A promoter in both cell lines appears to be favorable for 
transcription. In fact, enrichment for acetylated histone H3 was greater for the COL4A6 A 
promoter than the COL4A6 B promoter in SCC-25 cells; this region was not associated 
with methylated H3K9. Therefore, some other mechanism that is not dependent upon 
histone modifications may exist to account for differences in relative expression. In one 
scenario, the megadalton size PIC assembled at the COL4A5 promoter could simply be 
too large to allow another complex to assemble only 292 bp away. Alternatively, PIC 
assembly at the COL4A5 promoter could result in a conformational change in DNA that 
is unsuitable for protein binding at the COL4A6 A promoter.  
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Silencing of COL4A5 and COL4A6 in SK-N-SH Cells 
In SK-N-SH cells, transcription initiation is prevented by histone modifications 
that facilitate heterochromatin formation. The COL4A5 and COL4A6 promoter regions 
were characterized by: 1) absence of RNAPII, 2) absence of acetylated histone H3, and 3) 
presence of H3K9me2. These findings correlate well with real time data, which failed to 
detect either transcript even using primers targeted to the 5′ end. Forced acetylation 
relieved repression of both genes as determined by treatment of cells with TSA, while 5-
Aza had little or no effect on expression. This suggests that DNA methylation does not 
play a role in silencing collagens in this cell line and is supported by bisulfite data, which 
revealed very few methylated CpGs. Those CpGs that were methylated were probably 
associated with the inactive X chromosome.   
These data allow for a working model of repression to be proposed (see Figure 
13). An, as yet, unidentified trans-acting repressor binds to specific sequences in the 
promoter region and functions to recruit HDACs. It is only after deacetylation of histones 
that HMTs can methylate histone H3K9; presumably, other repressive marks work in 
conjunction with H3K9me2. The resulting closed chromatin creates an environment that 
is unfavorable for binding of the transcription machinery. Constitutive expression of the 
repressor complex ensures stable repression of COL4A5 and COL4A6. 
ChIP analysis showed enrichment of HP1 in the promoter region, suggesting that 
HP1 may be involved in repression of collagens in SK-N-SH cells. HP1 is known to 
silence genes through binding of H3K9me2. In contrast to the “spreading” mechanism 
important in silencing constitutive heterochromatin, HP1 associates with one nucleosome  
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Figure 13 Proposed model for silencing of collagen genes in SK-N-SH cells. The repressor complex 
binds to the promoter region and recruits HDACs. Histones become deacetylated allowing for methylation 
of histone H3K9 by HMTs. COL4A5 and COL4A6 are stably silenced through constitutive expression of 
the repressor complex. See text for more details. R, repressor; RE, repressor element; Ac, acetyl group; me, 
methyl group. 
 
 
near the promoter region to silence genes in euchromatin (73,91). This is evidenced in the 
current study by enrichment of HP1 at two discrete locations, one near the TSS of 
COL4A5 and another near the TSS of COL4A6 B. The precise mechanism by which HP1 
silences genes is not well understood, although HP1 has been shown to interact with 
repressors as well as components of the transcription machinery (92,93). In addition, HP1 
 
 72
has recently been shown to mediate interactions between DNMT1 and the HMT, G9a 
(94). Although HP1 may play a role in silencing collagens in SK-N-SH cells, enrichment 
of HP1 could be due to associations with the silent X chromosome. ChIP analysis should 
be carried out on the other three cell lines before more conclusions can be drawn.  
In addition to those discussed here, other mechanisms may be involved in the 
stable silencing of COL4A5 and COL4A6. For example, replication timing has been 
shown to be an important layer of repression. Tissue-specific genes replicate early in the 
tissues in which they are expressed and late in the tissues where they are turned off. 
Furthermore, DNA replicated early in S phase gets re-packaged in acetylated histones, 
whereas late replicating DNA is associated with HDACs (70,95).  
 
Selective Activation of COL4A5 in HT-1080 Cells  
 HT-1080 cells present a unique opportunity to study two genes whose promoter 
regions are intimately associated, but are not co-expressed. The COL4A5 gene is 
transcribed in this cell type, and, as expected, the promoter region is associated with 
RNAPII and acetylated histones. It has been proposed that a glomerular activator exists to 
promote selective transcription of COL4A5 (49). Two conserved, non-coding sequences 
identified in this study, -41K and 76K, may function as this activator as they were shown 
to enhance transcription of a reporter gene in HT-1080 cells. They were also found to be 
associated with acetylated histone H3. Consequently, these sequences may bind trans-
acting factors that interact with the COL4A5 promoter region, chromatin remodelers, and 
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other transcription factors to promote gene activation. Figure 14 displays the proposed 
model of transcription in HT-1080 cells.     
 The first evidence to suggest that DNA methylation is involved in regulating 
collagen expression comes from treatment of HT-1080 cells with the demethylating 
agent, 5-Aza. Expression of COL4A6 was dramatically increased upon treatment; 
however, no change was seen for COL4A5. This suggests CpG methylation is involved in 
the selective silencing of COL4A6. Indeed, bisulfite sequencing data revealed that the 
COL4A6 B promoter was heavily methylated, while the COL4A5 region remained 
relatively free of this modification.  
DNA in the COL4A6 A promoter region was unmethylated and histones were 
acetylated; however, no transcripts were detected by real time. Perhaps DNA methylation 
at the COL4A6 B promoter can also act to silence transcription of COL4A6 A. 
Alternatively, the mechanisms discussed earlier for SCC-25 and HEK-293 cells may also 
be at work in HT-1080 cells.    
The question then becomes what is the mechanism by which CpG methylation 
exerts its effects. Proteins with MBDs have been shown to bind methylated DNA and 
recruit HDACs to modify chromatin. Based on the data presented here, it does not appear 
that CpG methylation functions in this manner as acetylation was not sufficient for gene 
activation. ChIP analysis showed the COL4A6 B promoter was acetylated under normal 
conditions, and even treatment with TSA to fully acetylate histones had no effect on 
expression. Histone acetylation, therefore, is most likely necessary, but not sufficient for 
gene activation. Instead it is possible that methyl CpG functions directly by inhibiting the  
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Figure 14 Proposed model for selective activation of COL4A5 in HT-1080 cells.  Methylation of CpG 
dinucleotides in the COL4A6 B promoter functions to prevent binding of an unidentified activator, thereby 
inhibiting transcription. Activation of COL4A5 is mediated through interactions among HATs, GTF, and an 
unidentified glomerular activator. RNAPII is recruited and transcription is initiated.  
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binding of an activator to the promoter region to prevent transcription initiation (see 
Figure 14). This has been shown to be the case for several transcription factors (74,75). 
On the other hand, methyl CpG can actually bind repressor complexes to negatively 
impact transcription. In both models, the repressive mark is stable through successive cell  
divisions by maintenance DNMTs. More experiments are certainly necessary to 
determine the exact role of DNA methylation in this cell line.  
 Other experiments have shown expression of collagens to be inversely correlated 
with DNA methylation. One recent study evaluated the methylation profiles of the 
COL4A5 and COL4A6 promoters in colorectal cancers and found hypermethylation to be 
associated with loss of expression of both collagen alpha chains (96). Methylation of the 
COL4A6 B promoter, however, was not assessed making the current study the first to 
look at this region. It is important to mention that, by definition, the collagen promoter is 
not a CpG island. Nonetheless, based on the data presented here and the previous study, 
this should be re-considered. While computational analyses are undeniably useful, 
experimental data outweigh any method of prediction.   
 
Summary and Future Directions 
 Cell type-specific epigenetic marks, including histone modifications and DNA 
methylation, contributed to regulation of the type IV collagen genes, COL4A5 and 
COL4A6. Regulation occurred at transcription initiation, although mRNA processing and 
other post-transcription mechanisms of control may also contribute to steady state 
transcript levels. In addition, evidence to suggest that conserved, non-coding sequences 
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modulate collagen expression was provided. More experiments must be carried out to 
determine whether or not these findings function in vivo.  
Although these data shed light on collagen gene regulation, several fundamental 
questions remain unanswered. For example, in cell lines expressing COL4A6, transcript 
levels of B were higher than A. What is the functional significance of this and how are 
these differences mediated? Are these differences occurring in vivo? In previous 
experiments using RT-PCR, both transcripts were found to be expressed in kidney, lung, 
and placenta, although relative transcript levels were not determined (48). Only COL4A6 
B was shown to be expressed in the bladder suggesting that functionally significant 
differences do indeed exist (97). Determining how COL4A6 A and B operate should be 
the focus of future research.  
 Questions regarding transcription rates of COL4A5 and COL4A6 also exist. 
Specifically, do transcription rates reflect trimer composition, i.e. 2:1 ratio of COL4A5 to 
COL4A6? The ratio of steady state levels of COL4A5 and COL4A6 has been shown to be 
different for different tissues; however, these studies did not determine the actual rates of 
transcription. Significantly, transcription rates do reflect trimer composition for COL4A1 
and COL4A2 in cell lines, although steady state transcript levels do not. This suggests 
transcription and post-transcription mechanisms of regulation exist. Perhaps the same 
will hold true for COL4A5 and COL4A6.  
 Although the COL4A5-COL4A6 promoter region has been extensively 
characterized, the functional significance of CTCBF, Sp1, and CCAAT binding protein 
remains unknown. Binding motifs for these proteins are located in the COL4A5-COL4A6 
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promoter as well as the COL4A1-COL4A2 promoter and introns 1 of both genes. All 
three proteins have been shown to bind to their respective motifs and facilitate 
transcription of COL4A1 and COL4A2. With regards to COL4A5 and COL4A6, deletion 
constructs tested in vitro suggested that CCAAT binding protein and CTCBF do not 
contribute to gene activation (25). The possibility exists that different experimental 
conditions may reveal the importance of these proteins in transcription, thus studies 
aimed at determining their role should be conducted in the future.  
 Finally, do mechanisms exist to coordinate type IV collagen expression? For 
example, COL4A5 and COL4A6 expression appears to be coupled through the presence 
of a bi-directional activator; the resulting protein products form the α5.α5.α 6(IV) trimer. 
Transcription can be uncoupled through absence of this activator and presence of 
additional elements to selectively transcribe COL4A5. The COL4A5 gene is unique in 
that its protein product can also partner with α3(IV) and α4(IV). What mechanisms exist 
to account for expression of COL4A3, COL4A4, and COL4A5? This question has been 
addressed by studying Alport syndrome, which is caused by mutations in any one of 
these three genes. The results, however, are conflicting. Studies using human fibroblasts 
and canine models of the disease suggest that expression is not coordinated, while 
another canine model of Alport syndrome provided evidence to suggest that expression of 
COL4A3, COL4A4, and COL4A5 is coordinated (32,98,99). The particular mutation 
involved in each case may contribute to differences in transcript expression, thus studies 
in wild-type cells should be conducted.   
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In addition to these fundamental questions regarding type IV collagens, more 
research should be dedicated to delineating the role of COL4A5 and COL4A6 in disease. 
For example, mutations in COL4A5 are causative for the X-linked form of Alport 
syndrome (XLAS). In approximately 50% of human cases, the underlying mutation can 
not be identified in the coding region, promoter, or splice sites (100). It is possible that 
mutations in intronic, cis-acting elements, such as those identified in this study, can 
contribute to the disease phenotype. In addition, epigenetic changes may be causative for 
XLAS. Some patients presenting with the disease have normal trimer formation, but 
decreased amounts in the extracellular matrix as determined by immunohistochemistry. 
Perhaps these cases are characterized by abnormal mRNA expression that results from 
changes in histone modifications or partial DNA methylation of the promoter. These 
issues should be further explored as efficient and accurate diagnosis is imperative for 
proper treatment.  
 In addition to Alport syndrome, the role of type IV collagens in cancer has been 
widely studied. Cancer cells have been shown to produce MMPs that function in 
remodeling the extracellular matrix. Disruption of the type IV collagen network occurs, 
allowing for cancer cell migration.  Indeed, numerous studies have shown that changes in 
composition and/or loss of the collagen network correlates with tumor invasiveness. The 
majority of studies to date have focused on protein levels; however, disturbances in the 
type IV collagen network have also been shown to result from down-regulation at the 
mRNA level. As mentioned previously, hypermethylation of the COL4A5-COL4A6 
promoter resulted in absence of the corresponding transcripts and proteins in colorectal 
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cancer. These changes provide a unique opportunity to reverse aberrant expression levels 
and potentially halt cancer metastasis. It is likely that epigenetic changes in type IV 
collagens will be described for other types of cancer as well. Findings from the current 
study regarding the role of epigenetic modifications in gene regulation will undoubtedly 
aid in future research.    
 In conclusion, data generated from this study have provided insight into 
regulation of COL4A5 and COL4A6 and will certainly aid in answering the fundamental 
questions outlined above.  
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